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Type I (Tc1) CD8+ T cells have been shown to be more effective than type II (Tc2) 
CD8+ T cells for adoptive cell transfer therapy in several tumor models.  Migration 
differences between Tc1 and Tc2 cells were previously proposed to contribute to this 
difference in therapeutic efficacy.  In order to evaluate Tc1 and Tc2 migration in vivo, we 
developed a model using transfected EL-4 thymoma tumor cells expressing the p33 peptide 
antigen from lymphocytic choriomeningitis virus (p33.EL-4).  We used P14 mice, which are 
transgenic for the T cell receptor specific for p33 peptide that is expressed by these p33.EL-4 
tumors. We crossed UBI.GFP mice that ubiquitously express GFP with the P14 mice, in 
order to generate mice that express both GFP and the p33-specific TCR in the CD8+ T cell 
population.  Splenocytes from these mice were cultured to generate Tc1 and Tc2 cells, which 
were injected intraveinously into tumor-bearing mice.  Donor cells were phenotyped before 
transfer and on days 3 and 7 after transfer. The CD8+ T cells were examined for GFP and 
adhesion molecule expression by flow cytometry.  We examined gene expression of T-bet 
and enzymes important for selectin ligand glycosylation in Tc1 and Tc2 cultures, as well as 
the gene expression of cytokines, chemokines, and chemokine receptors in Tc1 and Tc2 
treated mice.  
We found significantly more Tc1 than Tc2 cells in TDLNs and tumors on days 3 and 
7 after transfer.  Both Tc1 and Tc2 donor cells were found in TDLN and tumor sites of p33 
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positive-positive tumors compared to sites of p33 antigen-negative tumors.   More 
importantly, all CD8+ T cells isolated from these tumors on days 3 and 7 after therapy, 
regardless of host or donor origin and Tc1 or Tc2 phenotype, expressed high levels of 
adhesion molecules important for T cell migration. This suggests that antigen does not alter 
the adhesion molecule expression of tumor infiltrating CD8+ T cells. These cells expressed 
high levels of CD44, leukocyte function-associated antigen-1 (LFA-1), and P-selectin 
glycoprotein ligand 1 (PSGL-1, CD162), suggesting a required “tumor infiltrating 
phenotype”. Before transfer and 3 days after transfer, Tc1 cells expressed higher levels of 
this tumor infiltrating phenotype compared to Tc2 cells.  Thus, increased Tc1 cell migration 
to TDLN and infiltration of tumors may be due to higher expression of a tumor infiltrating 
phenotype compared to Tc2 cells.  We found that T-bet expression is higher in cells from 
Tc1 vs. Tc2 cultures, which may promote the type I phenotype, including higher adhesion 
molecule expression.  However, we did not find a significant difference between the gene 
expression of selectin ligand glycosylating enzymes or PSGL-1 gene expression in Tc1 vs. 
Tc2 cells.  In addition, when we examined the gene expression of chemokines in the tumors 
of Tc1 vs. Tc2 treated mice, we found that type I interferon (IFN)−γ inducible protein (IP)-10 
is more highly expressed compared to macrophage derived chemokine (MDC) or 
macrophage inducing protein (MIP)-1α in either treatment group.  Also, donor and host 
CD8+ cells in Tc1 and Tc2 treated mice express chemokine receptor CXCR3 and cytokine 
IFN−γ, but no interleukin (IL)-4.  This data suggest that in addition to surface expression of 
adhesion molecules CD44, LFA-1, PSGL-1, expression of type I cytokine IFN-γ and 
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Immune response to tumors 
Development of tumors 
 Tumors develop as a result of uncontrolled growth of cancerous cells (1).  
Transformation of normal cells into cancerous cells involves several steps collectively 
termed carcinogenesis (1).  Initiation of carcinogenesis occurs as a cell or population of cells 
undergoes an event leading to DNA damage (1).  Internal (intrinsic) or environmental 
(extrinsic) events such as point mutations or ultraviolet radiation, respectively, can cause 
damage to DNA (1, 2).  Cells have repair mechanisms designed to recognize damage and 
restore DNA (1).  Unfortunately, not all DNA damage is repaired, and if the damage 
interrupts particular genes, this unrepaired damage leads to uncontrolled growth of the 
individual cells into an expanded cell population (1).  This expansion, or promotion stage, 
can be a result of mutations in tumor-suppressor or proto-oncogenes, which regulate cell 
cycle and proliferation (1).  The final stage of carcinogenesis, progression, is where these 
expanded cell populations undergo transformation into malignant cells, forming tumors (1).   
 Importantly, the immune system is able to respond to tumors and participate in the 
regulation of tumor growth (1-5).  It is believed that mechanisms in the immune system are 
capable of surveying the body for the generation of pre-cancerous cells and mediating the 
removal of these cells from tissues (1-5).  This process, known as immunosurveillance, has 
been off-set by the more recent understanding of the process called immunosubversion (1-5).  
Taken together, these models offer a complex dichotomy for not only immune system 
contributions to tumor cell rejection but also progression (1-5).  Furthermore, it is currently 
thought that tumors progress uncontrollably without intervention when the balance is shifted 




 Our understanding of the immune system and its response to tumors has come a long 
way since the original proposal by Ehrlich in 1909 that one role of the immune system is to 
reject an “overwhelming frequency” of carcinomas (3, 4).  Later, in the next half-century 
Burnet would propose the term “immunosurveillance” for the immune system’s role in 
recognizing tumor cells and mounting a response against tumor antigens capable of clearing 
the tumor cells prior to the presentation of clinical symptoms (6, 7).   Thomas also agreed 
with this theory, suggesting that the body must have mechanism(s) for managing the 
inevitable development of mutated cells and that immune mechanisms are a plausible 
candidate (8).   Due to the vast knowledge concerning tumor cell recognition and clearance 
by immune mechanisms, the current model of immunosurveillance is rather complicated 
compared to these earlier versions, which were quite simplistic but fitting with knowledge in 
the field at that time (1-8).   
  The theory of immunosurveillance has two major components: 1) Tumor cells are 
recognized by immune cells; and 2) Immune responses can eliminate tumor cells (1-4).  
Natural killer (NK) cells and cytotoxic CD8+ T lymphocytes are key components of anti-
tumor responses because they effect cell-mediated killing of targeted tumor cells (1-4).  NK 
cells recognize and kill target cells based on their expression of ubiquitous proteins, such as 
laminin, coupled with the loss of major histocompatabilty complex (MHC) class-I molecule 
expression on the surface of target cells, including most cancer cells (1-4).  MHC class- I 
signals through the killing inhibitory receptor on NK cells to prevent target cell killing, so the 
loss of MHC class-I is detected by the lack of this inhibitory signal (1-4).  NK cells can also 
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be activated by detecting MHC-I-like molecules upregulated during stress responses (3).  
Indeed, the concept of immune recognition and response to stress also applies to T cell 
responses primed through contact with antigen presenting cells (APCs) (3).  Dendritic cells 
(DCs) are “professional” APCs thought to play an important role in tumor cell recognition 
and tumor antigen presentation to cells of the adaptive immune system (1-5, 9-11).  The 
“danger model” of tumor cell recognition proposes that expression of danger signals such as 
heat shock proteins by cells with damaged DNA may activate DCs, which then present tumor 
antigens to B and T lymphocytes of the adaptive immune response (3, 11).  B cells secrete 
large amounts of immunoglobulin that can bind epitopes on tumor cells promoting their 
rejection (1-4, 11).  T cell mediated tumor clearance is detailed below. 
 
CD8+ T cells responses to tumors 
T cells of the adaptive immune response recognize peptides presented in the context 
of MHC complexes on the cell surface, and recognition of target cell MHC:peptide 
complexes by the T cell receptor (TCR) can result in direct killing of antigen expressing 
cancer cells (1-4, 8-14).  Sequences encoding regions of TCRs recognizing the MHC are 
conserved, while sequences encoding regions that recognize the peptide within the MHC are 
highly variable and undergo recombination to generate a vast repertoire of TCR specificities 
(12).  Due to allelic exclusion, only one recombined TCR sequence is expressed per T cell 
(12).  Because of the unique specificity of an individual T cell’s expression of the TCR and 
the large number of T cells, the repertoire of peptide antigens that T cells can recognize is 
estimated to be 1x108 – 1x1011 (12).  This vast range of antigen recognition is important for T 
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cell responses against tumors, because tumor cells can express a wide variety of antigens (1-
5, 9-12).   
 Tumor antigens are presented by APCs in tumor draining lymph nodes (TDLNs), 
where a single T cell can expand into a clonal population of epitope-specific T cells (1-5, 9-
15).  This population includes effector cells as well as cells that will continue to develop into 
central or effector memory cells (10, 15).  T cells express accessory molecules with the TCR 
called CD4 or CD8 (12).  Each CD4+ T cell recognizes a specific peptide in the context of a 
specific MHC class-II complex, and CD4+ T cells include both helper (Th) and regulatory T 
cells (Tregs) that respond by secreting large amounts of cytokines (15-18).  Th cells can be 
further divided into type I (Th1) and type II (Th2), based on their secretion of type I and type 
II cytokines, respectively (17).  Effector CD8+ T cells also respond by secreting cytokines, 
but unlike CD4+ T cells, activated CD8+ T cells upregulate molecules related to cytolytic 
activity (17-19).  CD8+ T cells can actually kill tumor cells via cell to cell contact through 
engaging ligands with death domain/receptor motifs or by releasing perforin followed by 
granzyme B (1, 2, 5, 9-11, 18, 19).  Targeted tumor cells undergo apoptosis, which further 
promotes the immune response and can ultimately lead to further presentation of tumor 
antigens and tumor cell rejection (20, 21). 
 
Tumor antigens and antigen-loss variants  
Antigens expressed by cancer cells within tumors are generally classified as either 
tumor-associated antigens (TAAs) or tumor specific antigens (TSAs) (3, 12, 22).  While 
TAAs are normally expressed by some tissues but induced inappropriately in cancer cells, 
TSAs are only expressed on cancer cells (12, 22).  Dominant antigenic epitopes may be those 
 6 
epitopes that are expressed more abundantly by cancer cells and are highly 
immunogenic/antigenic, while minor antigenic epitopes may be those that are not expressed 
as abundantly and/or are minimally immunogenic (11, 12, 22).  Within the tumor mass there 
are a variety of cell types that express tumor antigenic epitopes, but generally they are either 
cancer cells or stromal cells (11, 12, 21-24).  Cancer cells are the cells derived from the 
original malignantly transformed cell, while stromal cells are cells supporting the growth of 
the cancerous cells (11, 21, 23, 24).  Stromal cells include bone marrow-derived immune 
cells and non-bone marrow-derived fibroblasts and endothelial cells (11, 21, 23, 24).  Tumor 
antigens can be shed from the cancer cells and their antigenic epitopes are then presented by 
MHC molecules on APCs in the TDLNs or on the nearby stromal cells (11, 20-24).  Killing 
of stromal cells has been shown to be an important and effective therapy for mediating tumor 
rejection (21, 23, 24).   
Although T cells clearly contribute to the rejection of tumors by directly and 
indirectly mediating cancer cell killing, T cells can also promote immunoselection (1-5, 9-11, 
25).  The following description is an overview of how CD8+ T cell responses against TAA or 
TSA promote the immunoselection process, where immune responses promote survival of 
cancer cell populations instead of rejecting them (1-5, 9-11, 25).  Animal models have shown 
that tumors can express more than one antigenic epitope recognizable by the T cell 
repertoire, which can therefore serve as T cell antigens (22).  Due to the unique specificity of 
T cells to respond to only one epitope antigen on one type of class I molecule, the response 
of T cells is restricted to a small number of dominant epitopes (11, 24, 25).  As the T cell 
response targets these specific dominant epitopes, cancer cells expressing sufficient levels of 
these epitopes may be killed by the T cells (11, 24, 25)  However, those cancer cells not 
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expressing these epitopes or those cells which did express the epitopes but have down-
regulated the expression of these epitopes may escape T cell killing (1, 11, 24, 25).  These 
antigen loss variant cells which lost epitope expression continue to persist and the tumor 
continues to grow, even though these cells may express other T cell antigenic epitopes, the 
so-called minor antigens (1, 11, 24, 25).  Following the loss of dominant antigenic epitopes, 
minor antigen-specific T cells may now be activated; leading to another round of antigen-
specific responses and cancer cell killing (1, 11, 24, 25).  As the cycle of antigen recognition 
and killing of cancer cells bearing these antigenic epitopes continues, eventually the T cell 
repertoire is exhausted or suppressed, unable to effectively respond to antigens that may be 
expressed on these cancer cells (1, 11, 24, 25).  The remaining cancer cells no longer express 
antigenic epitopes that are either recognized by the T cells or which can effectively stimulate 
a tumor-protective response, and the tumor burden increases (1, 11, 24, 25).  Even as new T 
cells are elicited from the thymus, they cannot compete with the increased tumor burden and 
this immunoselection favors the survival of cancer cells not expressing T cell antigenic 
epitopes capable of leading to effective tumor surveillance (1, 11, 24, 25).  Again, these 
cancer cells without T cell-stimulating antigenic epitopes are called antigen-loss variants (1, 
11, 24, 25).  Selection for these antigen loss variants in vivo has been demonstrated, and we 
are realizing that immunoselection may also be a product of immunosubversion, described 
below (1, 2, 9, 11, 23, 25).  
 
Immunosubversion 
Even though immune responses can clearly promote tumor rejection, immune 
responses can also contribute to tumor growth (1-5, 9-11, 25).  Immunoselection is one 
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aspect of the negative effects immune responses can have on tumor clearance (1-5, 9-11, 25).  
The cycle of immunoselection may be perpetuated by suppressive immune responses (1, 2, 4, 
9-11, 25).  Despite the positive effects of T cell responses towards promoting tumor 
rejection, some T cells can promote tumor growth by suppressing immune responses against 
tumors (1, 2, 5, 9-11, 25).  For example, Tregs suppress immune responses through the 
production of interleukin (IL)-10 and transforming growth factor-β (TGF-β) (11, 15, 16, 25).  
Additionally, other suppressive cells in the tumor microenvironment also promote 
suppression of effective anti-tumor responses (1, 2, 5, 9-11).  These cells include myeloid 
suppressor cells and even CD8+ T suppressor cells (1, 2, 5, 9-11).  IL-10 is considered to be 
an important immunosuppressive cytokine produced by these cells and has been shown to 
promote the priming of type II responses by APCs (11).  Several studies have shown that 
therapies to reduce suppressive cell populations responding to tumors will result in increased 
tumor cell killing (26-29).  Therefore, part of the current paradigm of immunotherapies 
incorporates inhibiting suppressive activity and increasing CD8+ T cell activity (26-29). 
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Adoptive cell transfer therapy 
“Active” and “Passive” immunotherapy 
 Immunotherapy approaches to treat cancer may be classified as “active” or “passive” 
therapies (11).  Active therapies are those which promote the host immune response against 
tumor antigens, while passive therapies are those which transfer components of established 
immune responses to promote tumor cell clearance (11, 27).   Vaccines with peptide-pulsed 
APCs or genetically engineered tumor cells are examples of active therapy (11, 27).  These 
therapies are designed to facilitate priming of host anti-tumor responses, such as T and B 
lymphocytes (11, 27).  Instead, T cell or antibody therapies are passive therapies, where the 
priming of the T and B lymphocytes occurs under controlled conditions in vitro (10, 11, 26, 
29).  Therefore, active therapies promote a broader spectrum of tumor rejection, while 
passive therapies offer a specific mechanism of anti-tumor activity.  Passive T cell therapies 
are designed to target tumor cells and aid host responses, resulting in the complete rejection 
of tumor cells, the prevention of antigen loss variants or metastasis, and the establishment of 
immunologic memory to respond to any recurrent developments of cancer cells (10, 11, 26, 
29). 
 
T cell therapy 
Adoptive cell transfer (ACT) therapy with CD4+ or CD8+ T cells has been proven to 
be successful in promoting rejection of tumors in a number of animal tumor models, as well 
as in clinical trials (9-11, 26, 29).  Donor T cells are harvested from naïve animals or tumor-
bearing animals (or patients) and are then cultured under controlled conditions in vitro to 
prime and/or expand antigen-specific T cells (9-11, 26, 29).  If possible, T cells specific for 
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TSA and not TAA are generated in order to reduce any cross-reactivity with non-tumor cells 
that would result in autoimmune responses deleterious to the patient (9-11, 22, 26, 29).  In 
addition, the donor cells must be stimulated to obtain optimal effector function and migration 
properties (11, 26, 29, 30).  This is critical for the therapy to be effective, because not all T 
cells have the same ability to target tumor cells, migrate to tumor draining lymph nodes, or 
infiltrate into the tumors (11, 26, 29, 30).  It is important to note that, if possible, monoclonal 
T cells against TSA can be generated, which limits the generation of  contaminating 
suppressive T cells, including Treg cells, which must be removed from the donor cell 
population before transfer in order for the therapy to ultimately be effective (11, 26, 29, 31).  
Therefore, lymphodepletion is sometimes used to deplete the host lymphocytes, including 
activated suppressive cell populations, but this does not necessarily eliminate the 
development of effector cells subsequent to depletion (11, 26, 29).  These therapies also 
require that these epitope-specific effector T cells used in adoptive therapy exhibit the ideal 
phenotype, stage of differentiation, and migration properties to effectively seek out and 
destroy the tumor at the site of growth (11, 26, 29, 31-35).  Given the diversity of cancer cell 
origins and tumor locations coupled with the complex nature primary and metastatic tumor 
growth, studies discerning the critical properties needed by adoptively transferred cells to be 
most effective in therapy are vital to the ultimate success of ACT therapy.   
   
Phenotype of T cells for therapy 
One crucial factor which ultimately determines the effectiveness of ACT is the ability 
of adoptively transferred epitope-specific T cells to home to the TDLN as well as the site of 
the tumor, and to effectively infiltrate the tumor mass (10, 11, 26, 31).  While it was 
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originally believed that T cells with the highest cytolytic activity in vitro would be the most 
effective population for ACT therapy, it is now known that these cells actually confer limited 
tumor rejection activity in vivo (26, 32-35).   This is because while these cells were most 
effective at killing the tumor cells in vitro, they were significantly less effective in migrating 
to the site of the tumor and infiltrating the tumor mass (33-35).  This is due to the fact that 
activated T cells progress through various stages of activation before becoming memory cells 
(given a linear development of memory cells), and transition into these different activation 
stages are accompanied by changes in proliferation capacity, cytokine expression, and in the 
cell surface expression of molecules needed for optimal migration in vivo (26, 33-35).  
Immediately after stimulation, the T cells have high proliferative capacity, produce large 
amounts of IL-2, but low amounts of IFN-γ, and how low cytolytic activity in vitro (33-35).  
These early effector cells begin to down-regulate CD62L and up-regulate CD44 (33, 35).  
After subsequent stimulations, their proliferative capacity and IL-2 production decreases, 
while IFN-γ and cytotlytic activity increases (33, 35).  These intermediate and late effector 
stage T cells progressively down-regulate CD62L and up-regulate CD44 (33, 35).  
Interestingly, it is the early effector cells which have the highest anti-tumor activity after 
transfer in vivo (26, 33, 35).  It is believed that the expression of CD62L is important for the 
donor cells to home to the TDLNs for restimulation and subsequent tumor infiltration (11, 
26, 31, 33-35).  
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Type I (Tc1) and type II (Tc2) CD8+ T cell therapy 
Tc1 and Tc2 cells 
 CD8+ T cell therapy has been applied to treatment of many tumors including 
melanoma (10, 11, 26, 27, 29, 31).  Numerous animal studies have investigated the use of 
type I Tc1 vs. type II Tc2 CD8+ T cells for therapy (36-48).  Tc1 and Tc2 cells, like Th1 and 
Th2 cells, are generated in different cytokine conditions and/or by conditions or stimuli 
which generate different signaling patterns through the TCR (17, 49-52). Th1 and Tc1 cells 
are generated by inducing a stronger calcium flux signal, while Th2 and Tc2 cells are 
generated by activating a stronger protein kinase C (PKC) signal (50).  In addition, like Th1 
vs. Th2 polarization, we know that altered peptide ligands can generate Tc1 vs. Tc2 cells 
(50).  In vitro the Tc1 cells are normally generated by adding IL-12 /IFN−γ and anti-IL-4 
antibody to cultures during antigen-specific activation, while Tc2 cells are generated by 
adding IL-4 and anti-IFN−γ and anti-IL-12 antibodies, to stimulating culture conditions (49, 
52).  T cell cultures can be stimulated in vitro by adding antigenic peptides to whole 
splenocytes cultures, adding peptide-pulsed APCs to purified T cells, or by simply adding 
anti-CD3 and anti-CD28 antibodies to T cells (52).  It has also been reported that in vivo 
generation of Tc1 vs. Tc2 cells can occur depending on the T cell priming environment (51, 
53).  In two recent examples, exposure of animals to ultraviolet radiation (UV) prior to T cell 
priming through the exposed skin promotes the development of Tc2 cells, while animals 
vaccinated with 48 hour peptide-pulsed DCs, instead of 8 hour pulsed DCs, generated more 
Tc2 than Tc1 cells against the peptide antigen (51,53).  Therefore, it appears that the 
generation of polarized Tc1 and Tc2 cells can occur under natural conditions in vivo, and 
 13 
therefore understanding the differential effectiveness of these cells in anti-cancer responses 
represents an important step toward developing effective anti-cancer therapies. 
Although there are numerous methods for generating Tc1 and Tc2 cells, the function 
of these cell populations is consistent regardless of the methods used for generating these 
cells (52).  Tc1 cells secrete large amounts of IFN−γ, but Tc2 cells secrete limited amounts of 
IFN−γ and significant amounts of IL-4, IL-5, and IL-10 (17, 49-52).  Like Th1 and Th2 cells, 
Tc1 and Tc2 cells express type I and type II chemokine receptors (17, 54).  Tc1 cells express 
chemokine receptors CCR5 and CXCR3, but Tc2 cells express chemokine receptors CCR4 
and CXCR3 (17, 54).  In addition, these two polarized CD8+ T cell populations reportedly 
have similar proliferation and cytolytic responses in vitro and in vivo (49, 52).  This similar 
proliferative capacity and cytolytic activity by Tc1 and Tc2 cells in vitro suggested that 
antigen-specific Tc1 and Tc2 cells would be equally responsive in vivo and led to numerous 
investigations of Tc1 and Tc2 ACT tumor therapies.   
 
Efficacy of Tc1 and Tc2 therapy 
Over the past 15 years, a number of investigations have evaluated Tc1 and Tc2 
therapies, in both the B16 metastatic and EL-4 non-metastatic tumor models (36-48).  In 
contrast to the results expected from in vitro data (described above), several studies have 
shown evidence that cultured antigen-specific donor Tc1 cells are more effective than Tc2 
donor cells when transferred into tumor-bearing host animals (37, 39-41, 45, 46, 48).  For all 
of these studies, antigen-specific T cells were generated in vitro and then transferred i.v. into 
recipient mice either on the same day as tumor injections or on empirically-determined days 
following tumor injections (36-48).  In some cases both Tc1 and Tc2 therapies were effective 
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at reducing tumor growth or promoting tumor rejection, but in other cases Tc2 treated 
animals showed no improvement compared to controls (36, 38, 42-44, 47).  Studies that did 
report effective therapy with Tc2 cells demonstrated that Tc2 therapy, while effective, does 
require significantly more donor cells than Tc1 therapy (37, 39).  As a result of these 
findings, the properties of Tc1 and Tc2 cell function during tumor therapy were investigated.   
Functions of CD8+ T cells mentioned above include proliferation, cytolytic killing, 
and cytokine production (17, 18).  Proliferation and cytolytic killing efficiency appears to be 
the same for Tc1 and Tc2 cells both in vitro and in vivo (17, 37-40, 45, 49, 52).  The only 
clear difference between these Tc1 and Tc2 cells to date is their cytokine profile listed above:  
Tc1 cells secrete large amounts of IFN−γ, and Tc2 cells secrete little IFN−γ but large amount 
of type II cytokines such as IL-4, IL-5, and IL-10 (17, 49-52).  Whether type–specific 
cytokine production by donor cells is required for effective Tc1 or Tc2 therapy is not clear, 
because studies evaluating the importance of effector-cell cytokines have shown conflicting 
results (37-40, 43, 44, 47, 48).  However, donor or host derived IFN−γ appears to be 
important for therapy (37-41, 43, 44, 46-48, 55, 56).  This is supported by evidence that 
IFN−γ promotes upregulation of chemokines shown to increase the recruitment of tumor 
infiltrating T cells (11, 47, 48, 57-59).  This suggests that therapy with Tc1 cells, which 
produce more IFN−γ compared to Tc2 cells, would result in increased infiltration of tumors 
by T cells.  Indeed, one study found higher numbers of host T cells in TDLNs of Tc1 vs. Tc2 
treated animals, and another study concluded that IFN−γ signaling to host cells was 
important for increased host tumor infiltration during Tc1 therapy (Tc2 therapy was not 
examined) (39, 47, 48).  What was still unclear was whether donor Tc1 and Tc2 cells 
infiltrate tumors with equal efficiency.  It is important to determine whether Tc1 or Tc2 
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therapy promotes not only donor, but also host cell infiltration into the tumors and migration 
to TDLNs, because trafficking of T cells to TDLNs and tumors has been shown to indicate a 
positive prognosis in patients who have been given immunotherapy (9, 11).   Thus, we 
evaluated donor and host cell migration and tumor infiltration in Tc1 and Tc2 treated animals 
in our study. 
 
Tc1 vs. Tc2 trafficking  
Although it was not yet understood or clearly demonstrated, a few observations from 
two key studies suggested that Tc2 cells may have different migration properties than Tc1 
cells:  1) Tc1 cells were found in higher number in TDLNs than Tc2 cells, 2) Tc2 cells 
arrived later in the TDLNs than Tc1 cells, and 3) Tc2 cells appeared to preferentially migrate 
to the spleen (39, 40).  One of these two studies has evidence to suggest that Tc1 cells also 
infiltrate tumors in higher numbers than Tc2 cells, however, due to limitations of the study, 
statistical significance could not be evaluated (40).  Importantly, both studies which support 
migration differences between Tc1 and Tc2 cells were done in s.c. tumor models (39, 40).  
Other studies have suggested that Tc1 and Tc2 cell tumor infiltration is similar in a 
pulmonary metastasis tumor model (37, 43).   
The phenotype of Tc1 and Tc2 cells has been evaluated to a limited extent, 
particularly in regard to migration properties (52).  As stated earlier, it has already been 
shown that expression of adhesion molecules CD44 and CD62L are important for effective 
tumor therapy (26, 32-35).  One study examined the expression of activation-associated 
surface markers and function of Tc1 and Tc2 cells derived under various culturing methods 
(whole splenocyte cultures with peptide, T cell cultures with generated APCs and peptide, 
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and T cells with anti-CD3 with anti-CD28 antibodies) (52).  This study found different levels 
of CD44 and CD62L expression, based on culture methods (52).  In general, CD44 was 
slightly higher and CD62L was higher overall on cells in the Tc1 culture compared to cells in 
the Tc2 culture (52).  Since CD62L is important for homing to LNs, the higher expression of 
this molecule by Tc1 cells in vitro could lead to higher migration to TDLNs by Tc1 vs. Tc2 
cells (60).  If Tc1 cells do actually migrate and infiltrate tumors more effectively than Tc2 
cells, it is reasonable to expect a higher number of Tc2 cells would be required for therapy, 
and it appears that this is the case (37, 39).  Tc2 therapy has been shown to require up to 100-
fold more cells than Tc1 therapy to demonstrate equivalent efficacy (39).  (Also, because Tc1 
and Tc2 cells express different levels of chemokine receptors, it is presumed that these cells 
would respond with different efficiencies to various chemokines (17).)  Taken together, these 
data suggest that Tc1 cells migrate more effectively than Tc2 cells to TDLN, thus requiring a 
smaller population of donor cells for effective therapy.  Because T cell migration and tumor 
infiltration are important for effective tumor clearance and tumor therapy, if Tc1 and Tc2 
cells have different migration and tumor infiltration properties in vivo, these differences 
could contribute to the differnences in therapeutic efficacy for Tc1 vs. Tc2 therapy. 
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T cell trafficking and adhesion molecules 
Migration  
Although little is known about Tc1 vs. Tc2 cell trafficking specifically, we do know 
that T cell trafficking is regulated by a variety of molecules, including chemokines, which 
bind to chemokine receptors on T cells, and numerous molecules expressed by the T cells ( 
ligands and receptors), which are important for T cell adhesion (60).  (These molecules are 
collectively referred to as adhesion molecules in this document as an abbreviated form of a 
list of molecules.)  Chemokines play an important role in attracting T cells to specific sites of 
inflammation or to specific tissues (60).  Adhesion molecules control T cell retention at 
certain sites as well as migration across endothelium (60-64).  Different chemokines and 
adhesion molecules are important for naïve, effector, and memory T cell migration (60, 61).  
Naïve T cells circulate through the blood, lymphatics, and secondary lymphoid organs 
including lymph nodes (LNs) (60, 61).  Naïve T cells express both CD62L and chemokine 
receptor CCR7 that binds CCL19 and CCL21, which are critical for T cell homing to LNs 
(60, 61, 65).  T cells enter into LNs from the blood by crossing high endothelial venules (61, 
63, 65).  After activation in the LNs following contact with APCs, effector T cells down-
regulate CCR7 and CD62L but up-regulate other adhesion molecules and chemokine 
receptors for migration to the site of inflammation (61, 64, 65).  Memory cells are subdivided 
into two distinct subsets- central and effector memory cells (61, 64).   Central memory T 
cells circulate similarly to naïve T cells and express molecules important for LN homing (60, 
61, 64).  Effector memory T cells do not circulate through LNs, but instead migrate primarily 
through non-lymphoid tissues (60, 61, 64).  As mentioned briefly above, the T cells used in 
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ACT therapy must have an appropriate phenotype for migrating to TDLNs and tumors (26, 
33-35).   
In addition to the expression of the appropriate chemokine receptors and homing 
molecules such as CCR7 and CD62L, the expression of cell surface receptors that facilitate 
loose or tight adhesion and transendothelial migration is an important component needed for 
appropriate T cell trafficking (60-64).  These adhesion and migration processes are needed 
for T cells to migrate from one site to another when crossing vasculature (60-64).  As stated 
above, T cells cross high endothelial venules to enter into LNs (including TDLNs), and in 
order for T cells to infiltrate inflamed tissues or tumors they must cross the activated 
endothelium at the site of inflammation (60-64).  Specific chemokines recruit activated T 
cells to the inflammation site, such as macrophage inducing protein (MIP)-1α, macrophage 
derived chemokine (MDC), or IFN-inducible protein (IP)-10, which bind chemokine 
receptors CCR5, CCR4, and CXCR3, respectively (9, 11, 17, 30, 46, 54, 57-61).  The 
binding of these or other chemokines expressed by activated endothelium signals through G-
coupled protein chemokine receptors to promote changes in adhesion molecules on T cells 
(60, 66-70).  These changes include switching from inactive to active conformation for some 
adhesion molecules (66-70).  The T cells then undergo loose and tight adhesion to the 
endothelium, followed by transendothelial migration through the endothelium (62, 63).  
Below is a brief review of several of these adhesion molecules important in CD8+ T cell 
adhesion, diapedesis, or infiltration, and what is known about their differential expression on 




L- selectin (CD62L)  
Adhesion molecules regulate each step of this migration into an inflamed site (60-70).  
These adhesion molecules include integrins, selectins, and their ligands (60-70).  Selectin 
CD62L binding is critical for effective T cell homing to LNs (65).  CD62L has been reported 
to be expressed higher on Tc1 cultures compared to Tc2 cultures (52).  There are two other 
known selectins, E- and P- selectin (65).  Selectins are expressed on bone-marrow derived 
cells (including T cells) as well as endothelial cells (65).  Members of the selectin family 
have similar structure:  C-type lectin, with N-terminal lectin domain, an epidermal growth 
factor-like domain, repeat sequences, followed by C-terminal trans-membrane and 
cytoplasmic domains (65).  While L-selectin is important for homing to the LNs, it can also 
play a role in adhesion to peripheral node addressin on inflamed endothelium (65).  
Expression of CD62L is regulated in part by proteolytic cleavage of surface bound CD62L, 
which in turn has been shown to upregulate CD62L gene expression (71).  In addition, the 
soluble CD62L generated by cleavage of the surface bound CD62L can inhibit T cell 
migration in vivo, particularly the homing to LNs (72).    Therefore, we examined the 
expression of CD62L by donor cells.  Examining CD62L expression by donor cells not only 
aids in determining the activation/memory phenotype of the cells but also may suggest 
whether CD62L expression is important for regulating donor cell migration into TDLNs, 
where the donor cells encounter APCs presenting tumor antigens.  
 
P- selectin glycosylated ligand-1 (CD162, PSGL-1) 
P-selectin glycoprotein ligand-1 (CD162, PSGL-1) is the primary T cell ligand for P-
selectin on activated endothelium (63, 65).  PSGL-1 functions as a homodimer, which 
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requires glycosylation of the sialic acid backbone structure for optimal binding to selectins 
(65).   It is expressed on all T cells, although not necessarily in the glycosylated form 
expressed on activated T cells (65).  PSGL-1 mediates loose adhesion or rolling of T cells 
along activated endothelium (63, 65).  There is evidence that PSGL-1 has other functions, as 
well (73-75).  Cross-linking of PSGL-1 can induce apoptosis through the mitochondrial 
pathway, Syk signaling through ezrin/radixin/moesin (ERM) proteins, as well as upregulation 
of colony stimulating factor-1 transcription through Syk (73-75).  PSGL-1 has also been 
implicated in chemotactic T cell responses not dependent on the adhesion function of PSGL-
1 (76).  PSGL-1 expression and function may be different between type I and type II T cells 
(65, 77).  In Th1 cells, it has been shown that cross-linking of PSGL-1 promotes the binding 
of integrin leukocyte function-associated antigen-1 (CD11a/CD18, LFA-1) to its ligand, 
intercellular adhesion molecule (ICAM-1), but the expression of optimally glycosylated 
PSGL-1 in Th2 cells is significantly impaired compared to Th1 cells (77, 78).  Differences in 
the glycosylation of PSGL-1 in Th1 and Th2 cells has been linked to differences in the 
expression of T-box 21 transcription factor (T-bet) and its regulation of glycosylating 
enzymes (77-78).  PSGL-1 expression and role for migration of Tc1 vs. Tc2 cells is still 
unknown and differences in PSGL-1 exprsesion may contribute to the observed differences 
in Tc1 vs Tc2 migration in vivo.  Differences in the level and regulation of PSGL-1 
expression by Tc1 and Tc2 cells may affect their transendothelial migration in a manner 
similar to that observed for Th1 and Th2 cells.  Therefore, we examined the expression of 
PSGL-1 on Tc1 and Tc2 donor cells in vitro and in vivo. 
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Leukocyte function-associated antigen-1 (CD11a/CD18, LFA-1) 
Before-mentioned LFA-1 is an integrin adhesion molecule (66-70).  Integrins are 
heterodimers of alpha and beta subunits and have inactive and active conformations (62).  
LFA-1 consists of subunits αL and β2, both containing several domains including 
cytoplasmic domains for signaling (69, 70).  Chemokine signaling through small GTPases 
promotes the change in LFA-1 conformation from inactive to active, changing from low 
affinity to the highest affinity (69, 70).  LFA-1 is then able to readily bind ICAM-1 (as well 
as ICAM-2 or ICAM-3) mediating tight adhesion of T cells to the activated endothelium (66-
70).  LFA-1 is also able to bind molecules at the tight junctions between endothelial cells, 
such as junctional adhesion molecules, and mediate migration across the endothelium (67, 
68).    Like PSGL-1, LFA-1 can also mediate signaling (69, 70).  Cross-linking of LFA-1 
leads to signaling through cytohesin-1 to MAP kinases (69).  Due to the adhesion and 
signaling functions of LFA-1, it is interesting that LFA-1 localizes to lipid rafts and 
redistributes on the cell surface (69, 70, 79-81).  LFA-1 localizes initially to the middle of 
SMACs and then moves to the peripheral SMAC after TCR signaling, as the TCRs centralize 
(70).  In activated T cells, the TCRs and LFA-1 localize similarly, forming the 
immunological synapse, a ring of molecules at the junction between T cells and target cells 
(70).  Thus, conformation, signaling, and distribution of LFA-1 are important for T cell 
functions (66-70, 79-81ref).  LFA-1 has been shown in vitro to promote Th1 cell migration in 
conjunction with CD44, another adhesion molecule that localizes within the SMAC and 
immunological synapses (82). Thus, LFA-1 is an important molecule in mediating T cell 
migration and signaling functions.  Whether Tc1 and Tc2 cells express LFA-1 similarly and 
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whether it functions efficiently in both cell populations is unknown.  We examined the 
expression of LFA-1 by Tc1 and Tc2 donor cells in vitro and in vivo. 
 
CD44 
CD44 molecules are class I transmembrane glycoproteins encoded by one gene (83-
85).  At least 10 isoforms are generated through alternative splicing and post-translational 
modifications (83-85).  CD44 is upregulated after T cell activation and is also expressed on 
memory cells, as noted previously (61, 64). As could be expected due to the variety of CD44 
isoforms, CD44 has a variety of functions (83, 84f).  CD44 can function as a co-receptor to 
mediate signaling, although whether CD44 can directly mediate signal transduction has not 
yet been determined (83, 84).  A few of the signaling proteins that associate with the 
cytoplasmic tail of CD44 are Rho kinase, PKC, and the TCR signaling molecules LCK and 
FYN (83, 84).  We are only beginning to understand the complex nature of CD44 signaling.  
Importantly, CD44 interacts with the extracellular matrix and binds hyaluronic acid (HA) 
(83, 84).  As stated above, the adhesion function of CD44 is important for Th1 cell 
transendothelial migration, but not for Th2 transendothelial migration (82).  CD44 expression 
and function are not known for Tc1 and Tc2 cells.   Again, because Th1 and Th2 cells show a 
different dependence on CD44 for transendothelial migration in vitro and CD44 is involved 
in T cell signaling, we investigated the expression of CD44 by Tc1 and Tc2 cells. 
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Tumor infiltration by T cells 
Adhesion molecules 
All of the above adhesion molecules (CD62L CD44, LFA-1, and PSGL-1) have been 
implicated in T cell tumor infiltration (26, 33-35, 85-87).  The ability of T cells to infiltrate 
tumors is important for tumor clearance, especially for T cells used in tumor therapy (9, 11, 
26, 31).  Host responses to tumors requires CD62L and ICAM-1 (LFA-1 ligand) expression 
by T cells or other cells, as shown by knockout models (88).  It is proposed that this is due to 
the need for T cell activation in the TDLNs and for effective transendothelial migration, 
where CD62L and ICAM-1 play a role (88).  As shown in previous ACT therapy studies, 
CD62L and CD44 expression by donor cells is important for effective tumor therapy (26, 33-
35).  Again, CD62L expression is believed to contribute to homing of the donor cells to 
TDLNs for further antigen presentation and expansion of the donor cell population (26, 33-
35, 88).  Why CD44 is important is not yet known, however it may be to direct T cell 
migration in response the to extracellular matrix (83, 84).  In addition, cancer cells have been 
shown to express higher levels of HA compared to normal tissue (89).  Thus, the high 
expression of the CD44 ligand, HA, by cancerous tissue may help recruit T cells expressing 
higher levels of CD44 into the tumor (89).  In addition, PSGL-1 has also been implicated in 
tumor infiltration of CD8+ T cells because, CD8+ T cells with a high avidity for P-selectin 
have been shown to secrete more IFN−γ in response to tumors than cells with lower avidity 
for P-selectin (85).  Therefore, expression of these adhesion molecules may be important for 
tumor infiltration by donor Tc1 and Tc2 cells during ACT therapy (ref).  So, we examined 
the expression level of these molecules implicated in tumor infiltration by T cells in order to 
determine if, as expected, the cells would express high levels of these adhesion molecules. 
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The role of antigen in T cell migration 
Expression of antigen has been shown to affect T cell interactions with endothelial 
cells, particularly in vitro (90).  T cell recognition of antigen presented by the endothelial 
cells can lead to arresting of the T cells, killing of the endothelial cells, or transmigration (91-
93).  Several in vivo studies have shown that antigen presentation on inflamed endothelium 
promotes the transmigration of antigen-specific T cells (90, 93).  As we were conducting the 
following study, several labs independently reported that antigen-specific T cells infiltrate 
antigen-positive tumors more than antigen-negative tumors (94-97).  How the expression of 
antigen promotes T cell migration is unknown, and whether antigen presentation by 
endothelial cells promotes the migration of both type I and type II T cells similarly has not 
been reported.   
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Summary 
T cell responses are a critical component of the immune response against tumors, and both 
CD4+ and CD8+ T cells are being used effectively in ACT tumor therapies (9-11, 26-29).  
Several studies have recently examined the efficacy of Tc1 and Tc2 cell therapies in animals 
(36-48).   Although we and others have found that Tc1 therapy is more effective than Tc2 
therapy, why Tc1 therapy is more effective is not yet clear (37, 39-41, 45, 46, 48, 98).  After 
Tc1 or Tc2 cells are transferred i.v. the cells must migrate to tumor draining lymph nodes and 
infiltrate the tumor (10, 11, 26, 31).  Adhesion molecules and chemokines are important for 
effective T cell migration and tumor infiltration (9. 11, 60-68, 83, 84).  Differences in the 
trafficking of Tc1 and Tc2 cells have been proposed as a reason that Tc1 therapy is more 
effective than Tc2 therapy (39, 40).  We propose that the differences in Tc1 vs. Tc2 cell 
migration as well as the recruitment of host CD8+ T cells contributes to the differences in 
Tc1 vs. Tc2 therapy.  Therefore, in the following study, we investigated host CD8+ T cell and 
donor Tc1 vs. Tc2 cell migration and tumor infiltration in vivo (99). 
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A Model for Evaluating Migration and Tumor Infiltration 




ACT therapy is an effective treatment for tumors in animals and patients.  Tc1 cells 
have been shown to be more effective for tumor therapy than Tc2 cells.  In addition, studies 
have suggested that Tc1 cells migrate to tumor draining lymph nodes and tumors more 
effectively than Tc2 cells, however, differences in Tc1 and Tc2 cell migration are not yet 
understood.  In order to develop a model for evaluating Tc1 and Tc2 migration, we utilized 
both in vitro and in vivo approaches for studying T cell migration.  We found that the in vitro 
approach for evaluating T cell chemotaxis and transendothelial migration was difficult to 
duplicate for Tc1 and Tc2 cells.  The MS1-VEGF endothelial cell line we investigated for 
use in transendothelial migration studies expressed an activated phenotype after overnight 
stimulation, suggesting that these cells may be used for transendothelial migration studies.  
However, because optimal conditions for evaluating Tc1 and Tc2 cell chemotaxis were not 
obtained, our transendothelial migration model is not complete and requires additional 
development before it may be appropriate for further investigations.  Importantly, the in vivo 
model we developed, however, was highly reproducible and offers many advantages for 
examining Tc1 and Tc2 cell migration and tumor infiltration.  In this model, we established 
EL-4 thymoma tumors expressing the p33 antigen from lymphocytic choriomeningitis virus 
in host mice and injected these mice with polarized Tc1 or Tc2 cells generated in vitro from 
splenocytes of GFPxP14 mice.  These Tc1 and Tc2 cells are specific for p33, expressing the 
Vb8 T cell receptor specific for p33, and express green fluorescent protein (GFP).  In 
addition, these GFPxP14 Tc1 and Tc2 cells express type I and type II cytokine and 
chemokine receptor profiles, respectively.  Tc1 and Tc2 therapy using these cells yielded 
reduced tumor growth compared to untreated control animals, as observed in other Tc1 and 
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Tc2 tumor models, with Tc1 therapy providing higher reduction in tumor growth compared 
to Tc2 therapy.  Also, when we used this in vivo model to examine Tc1 and Tc2 migration, 
we were able to identify the donor Tc1 and Tc2 cells following transfer.  Tc1 cells could be 
found in TDLNs and tumors as early as day 1 after transfer.  Both Tc1 and Tc2 cells could be 
found in TDLNs and tumors on day 3, 7, and 10 following transfer.  While more Tc1 cells 
were found in TDLNs and tumors compared to Tc2 cells, the Tc2 cells appeared to be more 
abundant in the spleen compared to Tc1 cells.  Also, there appeared to be no significant 
difference between donor cell migration to contralateral and ipsilateral lymph nodes.  
Therefore, our GFPxP14 model is appropriate for investigating the migration and tumor 
infiltration of Tc1 and Tc2 cells in vivo, and these studies suggest that, indeed, Tc1 and Tc2 
cells may have different migration properties. 
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Introduction 
 CD8+ Tc1 and Tc2 cells have been used for tumor therapy in animals (1-13).  Studies 
have shown that Tc1 therapy is more effective at reducing tumor growth or rejecting tumors 
compared to Tc2 therapy (2, 4-6, 10, 11, 13).  A few studies have suggested that differences 
in Tc1 vs. Tc2 migration may contribute to this difference in therapeutic efficacy between 
Tc1and Tc2 cells (4, 5, 11).  In addition, in vitro studies have suggested that CD4+ Th1 and 
Th2 cells have different migration properties (14, 15).  Therefore, we proposed to evaluate 
Tc1 and Tc2 cell transendothelial migration in vitro and migration to TDLNs and tumors in 
vivo.  In order to do this, we first needed to develop a model to track the Tc1 and Tc2 cells. 
 Transendothelial migration assays are a method to evaluate T cell migration in vitro 
(14-17).  Transwell plates (Corning) with transwell filters separating lower and upper wells 
of the plate are used for this assay.  Chemokines are added to the lower well, and the 
migrating cells are added to the upper well.  After a desired time period, the cells within the 
lower well are counted.  In order to evaluate transendothelial migration, endothelial cells are 
cultured on the transwell filters (coated with extracellular matrix components).  This 
approach has been used to evaluate migration of CD4+ T cells, including polarized Th1 and 
Th2 cells (14, 15).  However, studies examining CD8+ T cell migration have focused on in 
vivo migration, and there is limited knowledge of CD8+ T cell migration in vitro (18).  In 
fact, to our knowledge, there are no reports of Tc1 or Tc2 migration in vitro. 
 Studies examining T cell migration in vivo have been limited by previous methods 
used to track the donor cells.  There have been three general approaches to tracking donor 
cells in vivo: intracellular labeling of amines, antibody detection of cell surface proteins, and 
GFP expression by transferred cells (4, 5, 7-9, 11-13, 18).  Labeling amines with 
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carboxyfluoroscein succinimidyl ester and other methods for labeling amines in cells are 
limited by the dilution of the labeling due to proliferation of the donor cells.  Using 
antibodies to detect donor cells based on expression of a unique cell surface protein, such as 
Thy1.1, has limited applications.  Because of the numerous applications for analyzing GFP 
expressing cells, including in vivo imaging, fluorescence microscopy, and flow cytometry, 
GFP-based methods are well suited for tracking cell migration in vivo (18).  Therefore, in 
order to distinguish the donor Tc1 and Tc2 cells from host CD8+ T cells, we proceeded to 
develop a model using GFP expression as a method to identify the donor cells. 
 In this study we worked to develop an in vitro transendothelial migration assay and an 
in vivo migration assay to evaluate Tc1 and Tc2 cell migration.  After finding less than 
optimal results with the transendothelial migration in vitro approach, we focused on 
developing an in vivo model. We developed a GFP-based murine model for investigating 
donor T cell migration and tumor infiltration in vivo.   GFPxP14 mice were generated by 
crossing UBI.GFP mice with P14 mice (19, 20).  T cells from GFPxP14 mice were 
characterized by flow cytometry ex vivo and after culture in vitro.   Tc1 and Tc2 donor cells 
were generated in vitro from GFPxP14 splenocytes and used for tumor therapy.  We then 
examined the spleens, TDLNs, and tumors of animals given Tc1 or Tc2 therapy to evaluate 
whether these Tc1 and Tc2 cells generated from GFPxP14 splenocytes could be identified 
after transfer into tumor bearing animals.  Our GFPxP14 murine model will allow for further 
investigation of T cell migration and tumor infiltration in vivo.  
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Materials & Methods 
Mice  
 C57BL/6J (B6) and UBI.GFP mice were obtained from The Jackson Laboratory (Bar 
Harbor, Maine) (19).  CD8 T cell vβ8 TCR transgenic P14 mice specific for LCMV peptide 
p33-41 (KAVYNFATC) in context of H-2Db were originally obtained from Dr. Pam Ohashi 
(20).  GFPxP14 mice were generated in our lab by crossing the UBI.GFP strain with the P14 
strain and using the F1 generation.   Spleens of GFPxP14 mice were used as the source for 
our donor cells, as detailed below.  B6 mice were used as recipient animals.  Female mice 
aged 8-12 weeks of age were used throughout these experiments.  All mice were maintained 
in specific pathogen free conditions by University of North Carolina’s Department of 
Laboratory Animal Medicine and all animal procedures were approved by the university’s 
Institutional Animal Care and Use Committee.   
 
Comparison of B6, P14, and GFPxP14 T cells 
The phenotype of T cell subsets in B6, P14, and GFPxP14 mice was determined by 
harvesting splenocytes, thymocytes, and lymph node cells of these mice, then staining the 
cells as indicated.  Cultures of splenocytes of these mice were stimulated with 2 µg/mL of 
ConcanavalinA and analyzed by flow cytometry.  
 
MS1-VEGF cells 
The MS1-VEGF cell line (ATCC) was maintained in DMEM (UNC-CH Tissue Culture 
Facility) (21).  When cells were 80-90% confluent, the cultures were split 1:3.  This cell line 
was originally developed from pancreatic endothelial cells, which were transfected with 
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vascular endothelial growth factor to promote the endothelial cell phenotype.  Cells were 
stimulated overnight with 1 ng/mL of IL-1β or TNF-α (R&D Systems) before analyzing the 
cell phenotype by flow cytometry. 
 
Tumor cell lines and construction of p33 encoding plasmid 
As a source of antigen-bearing tumor cells, our lab has previously generated LCMV peptide 
p33 -expressing EL4 thymoma tumor cells (EL-4.p33 cells, 22).  Briefly, EL4 cells obtained 
from ATCC were transfected with a PcDNA3.0 plasmid (Invitrogen) containing an insert 
encoding the LCMV peptide p33 linked to human beta-2 Microglobulin (22).  Linking 
peptides to human β2 microglobulin has been shown to enhance the peptide presentation in 
transfected cells, evidenced by increased specific lysis compared to target cells transfected 
with peptide alone (23-26).  P33.EL4 tumor cells were selected and maintained using RPMI-
1640 medium containing G418 (Sigma-Aldrich).  Transfection was confirmed by PCR and 
expression of the p33 antigen was confirmed by using the transfected cells as targets of P14 
T cells in cytolytic assays (22).  Both parental EL4 (p33 antigen-negative) cells and 
transfected p33.EL4 (p33 antigen-positive) cells were used in this study, as detailed below.   
 
Tc1/Tc2 cultures 
 Splenocytes from GFPxP14 mice were harvested and then stimulated at 5x106 cells/mL for 3 
days with 2µM p33 peptide (KAVYNFATC) along with 2 units/mL rIL-2 in RPMI medium.  
For Tc1 cells, we also added rIL-12 at 12.5ng/mL and anti-IL-4 antibody at 2.5ng/mL, but 
for Tc2 cells we added rIL-4 at 27.5ng/mL, anti-IL-12 antibody at 5.5ng/mL, and anti-IFN-γ 
antibody at 5.5ng/mL.  Recombinant murine cytokines and anti-murine cytokine antibodies 
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were all obtained from R&D Systems.   Tc1 and Tc2 cultures were both over 90% 
GFP+CD8+vβ8+ after three days of culture, as determined by flow cytometry.   
 
Flow cytometry analysis of surface molecule expression 
For cell surface expression analysis, cultured cells or cells from spleen, thymus, lymph node 
and tumor tissues were harvested.  Then, single-cell suspensions were made and the cells 
were stained for various cell surface markers, as indicated, using antibodies against the 
following:  for endothelial cell staining-- CD11b (Mac-1), CD31 (PECAM-1), CD54 (ICAM-
1), CD62P (P-selectin), CD102 (ICAM-2), and CD106 (VCAM-1); or for T cell staining--
CD4, CD8, Vβ8, and CD25 (Pharmingen).  Endothelial cells or lymphocytes were gated 
based on forward and side scatter.  Where noted, donor and host cells in TDLNs and tumors 
were identified by gating for GFP.  All flow cytometry samples were run on a FACSCalibur 
(BD Bioscience) and analyzed using FlowJo software (Treestar). 
 
Tc1 and Tc2 therapy 
1x106 EL4.p33 tumor cells were injected s.c. into the right ventral flank of B6 mice.  On the 
same day either 1x106 Tc1 or 1x106 Tc2 in 200uL of PBS were injected i.v. into the tail vein 
of these mice.  Control mice were injected with PBS alone.  Tumor growth was assessed 
every 2-3 days using calipers to measure perpendicular widths of the palpable tumors 
through day 18.  Tumor areas of animals within each treatment group were determined. Four 




Real Time RT- PCR 
Tc1 and Tc2 cultures were analyzed for IFN-γ, IL-4, CXCR3, CCR4, and CCR5 mRNA 
expression using TaqMan Gene Expression Assays from Applied Biosystems..  Total RNA 
was isolated from both cultures using RNEasy Minikits from Qiagen followed by DNase I 
treatment (Promega).  mRNA was converted to cDNA using Superscript III (Invitrogen).  
This cDNA was then used in Real Time PCR reactions using an ABI 7700 thermocyclyer.  
Samples were run in triplicate.  Data was analyzed according to the methods of Livak and 
Schmittgen (27).  Ct values for the cytokine and chemokine receptor genes were normalized 
to GAPDH expression for the same mRNA source.  The lowest level of gene expression was 
found for IL-4 expression in Tc1 culture. This expression level was set as a fold expression 




5µm pore transwell plate filters were coated with matrigel (BD Bioscience).  Medium 
containing MIP-1α chemokine (0ng/mL-100ng/mL as noted), was added to the lower well of 
the plated.  The matrigel coated filters were then inserted and 1x105 Tc1 or Tc2 cells were 
added to the upper well.  Loaded transwell plates were incubated at 37 for the duration of the 
assay.  After a certain period of time (4-28 hours as noted), the number of cells in the lower 
well was determined by counting the number of cells in a sample from the lower well using a 




Migration and Tumor Infiltration of Tc1 and Tc2 
5 or 7 days before donor cell transfer, B6 mice were injected s.c. in the right ventral flank 
with 1x106-1.5x106 p33.EL4 tumor cells.  For experiments examining the role of antigen, 
1x106-1.5x106 EL4 tumor cells were also injected into the mice but into the left ventral flank 
on the same day.  Then on day 0, 1x106 Tc1 or 1x106 Tc2 donor cells in 200uL of PBS were 
injected i.v. into the tail vein of these mice.  On days 3 and 7 after donor cell transfer, 
TDLNs (axillary and superficial inguinal lymph nodes) and tumors were collected then 




Experiments were repeated at least twice and data from one representative experiment is 
shown for each figure.  Where shown, a two-tailed Student’s T-test was utilized to test for 
significance with p ≤.05 considered significant.   
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Results 
In vitro and in vivo models have been used to evaluate T cell migration (14-18).  In 
order to develop a model to examine Tc1 vs. Tc2 migration, we applied both approaches.  In 
vitro models offer more control over variables that affect T cell migration, such as the 
amount and type of chemokines attracting the T cells.  In vitro models allow us to address the 
role of individual molecules and cells, while in vivo models are more difficult to control and 
interpret because of the complexity of in vivo systems.  GFP expression is an effective 
method for identifying and tracking T cells in vitro and in vivo (18, 28).  Therefore, we 
generated GFP expressing TCR transgenic mice specific for p33 antigen.  We then identified 
an endothelial cell line appropriate for in vitro migration assays and examined Tc1 and Tc2 
chemotaxis in vitro.  Finally, we developed an in vivo model for evaluating donor cell tumor 
infiltration. 
 
Generation and characterization of GFPxP14 mice 
 We chose to utilize GFP technology for tracking the Tc1 and Tc2 cells, because GFP 
expression can be detected in a number of assays/applications, allowing more options for 
evaluating Tc1 and Tc2 cell migration and tumor infiltration (18).  UBI.GFP mice (Jackson) 
express GFP under the human ubiquitin promoter (19).  We crossed these mice with P14 T 
cell receptor Vβ8 transgenic mice to generate GFPxP14 mice.  Importantly, the P14 mice are 
specific for the p33 antigen from lymphocytic choriomeningitis virus (20).  Previously in the 
lab, an EL-4 thymoma tumor cell line was transfected to express this p33 antigen (EL-4.p33, 
22).  This model would allow us to evaluate the migration and tumor infiltration by the p33 
antigen-specific T cells in vitro and in vivo. 
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We phenotyped the T cell populations in the GFPxP14 mice (F1 generation of the 
GFPxP14 cross) by flow cytometry.  We examined the T cell populations of thymus, spleen, 
and lymph nodes from GFPxP14 mice and compare these populations with T cells from B6 
and P14 mice (Figure 2.1).  Cells were stained with monoclonal antibodies against CD4, 
CD8, and Vβ8.  Lymphocytes were gated and analyzed for expression of these molecules and 
GFP.  Over 97% of cells in GFPxP14 mice express GFP, whereas cells from B6 and P14 
mice do not.  As expected, CD4+ cells are higher in tissues of B6 mice compared to either 
GFPxP14 or P14 mice, which have less than half as many CD4+ cells in the spleen and LNs.  
CD8+ cells are higher in the spleen and LNs of GFPxP14 and P14 mice compared to B6 
mice.  Importantly, over 80% of the CD8+ cells in the GFPxP14 and P14 mice are Vβ8+, 
while only 20% or fewer of the CD8+ cells in B6 mice express Vβ8. Therefore, the 
thymocytes, splenocytes, and lymph node cells of GFPxP14 mice are similar to those cells of 
P14 mice but express GFP.  Additionally, because previous studies using GFP to track T 
cells have reported that the T cells lost GFP expression after stimulation, we stimulated 
GFPxP14 splenocytes with Concanavalin A for 3 days and evaluated the phenotype of the 
cultured T cells (Figure 2.2) (28).  The culture maintained GFP expression and over 90% of 
the CD8+ cells were CD25+Vβ8+.  Therefore, the T cells of GFPxP14 mice are similar to 
the P14 mice T cells but express GFP, even after stimulation. 
 
GFPxP14 Tc1 and Tc2 cells 
Once we had developed the GFPxP14 mice and confirmed that T cells from these 
mice maintain GFP and Vβ8 expression after culture, we then confirmed that these cultured 
GFPxP14 splenocytes could be polarized to Tc1 and Tc2 cells.  Tc1 and Tc2 cultures were 
 46 
generated by stimulating GFPxP14 splenocytes for 3 days in polarizing conditions as 
described and the cultures were phenotyped for GFP, CD8, CD25, and Vβ8 expression using 
flow cytometry (Figure 2.3). These Tc1 and Tc2 cells derived from GFPxP14 splenocytes 
were GFP+CD8+ and over 90% of the cells are CD25+Vβ8+.  Real time RT-PCR was used 
to confirm the expression of IFN-γ, IL-4 and chemokine receptors indicative of type I and 
type II cultures (Figure 2.6) (29, 30).  Tc1 cells expressed higher levels of IFN-γ and CCR5 
than Tc2 cells, which expressed higher levels of IL-4 and CCR4.  Both cultures expressed 
similar levels of CXCR3.  Therefore, not only do GFPxP14 derived Tc1 and Tc2 cells 
express GFP and an activated T cell phenotype after stimulation, but the cells also express 
phenotypes indicative type I and type II polarization, respectively. 
 In order to evaluate whether the Tc1 and Tc2 cells behaved similarly to Tc1 and Tc2 
in other tumor therapy models, we transferred GFPxP14 Tc1 and Tc2 cells into mice 
receiving EL-4.p33 tumor cells (Figure 2.7) (1-13).  B6 mice were injected with 1x10^6 
tumor cells s.c. and injected with 1x10^6 Tc1 or Tc2 cells i.v. on the same day, while control 
animals received tumor cells s.c. and only PBS i.v.  (This dose of Tc1 and Tc2 donor cells 
falls within the range of donor cell doses reported by others to provide tumor protection 
(13).)  Every 2-3 days after the injections, animals were evaluated for palpable tumors.  Once 
tumors were palpable, tumor growth was evaluated every 3 days through day 18.  While both 
Tc1 and Tc2 treatments reduced tumor growth compared to control animals, the animals 
receiving Tc1 treatment had significantly reduced tumor growth compared to Tc2 treated 
animals, as well.  Interestingly, while animals given Tc1 therapy exhibit effective retardation 
of tumor growth starting on day 10, animals given Tc2 therapy do not exhibit impeded tumor 
growth until day 12.  After this initial delay in the reduction of tumor growth for Tc2 vs. Tc1 
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therapy, both therapies continue to be effective at reducing tumor growth through day 18 
compared to control animals.  Importantly, we continued to use this effective dose of Tc1 and 
Tc2 cells to develop our model to examine tumor infiltration.  Overall, these observations of 
Tc1 and Tc2 cell treatments show that Tc1 and Tc2 cells generated from GFPxP14 
splenocytes exhibit therapeutic efficacy similar to previous reports of Tc1 and Tc2 therapies  
--Both Tc1 and Tc2 therapies reduce tumor growth, but Tc1 therapy is more effective than 
Tc2 therapy (1-13).  
 
In vitro T cell migration assays 
 We sought to develop a transendothelial migration assay to be used to evaluate Tc1 
and Tc2 migration in vitro.  Two important components of transendothelial migration assays 
are the endothelial cells and the chemokine that is used to attract T cells (14-17).  For 
transendothelial migration assays, the endothelial cells are cultured until confluency on the 
transwell filters.  These filters are coated with extracellular matrix to aid in the adherence of 
the endothelial cells.  Endothelial cells used in transendothelial migration assays can either be 
endothelial cell lines or endothelial cells isolated mice and then cultured in vitro (15-17).  We 
chose to use a cell line for convenience and because cells isolated from mice have a risk of 
being contaminated with other cells, making their purity less reliable.  The MS1-VEGF cell 
line (ATCC) has been used previously to examine dendritic cell transendothelial migration 
(21).  These MS1-VEGF cells are pancreatic cells transfected to express vascular endothelial 
growth factor (VEGF).  Unstimulated endothelial cells do not express the necessary 
chemokines and adhesion receptors or ligands needed for T cell migration, so cultured 
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endothelial cells must be stimulated/activated with inflammatory cytokines before they can 
be used in transendothelial migration assays (14-17, 21).   
In order to determine whether the MS1-VEGF cell line was appropriate for use in the 
T cell transendothelial migration assay, we evaluated the phenotype of the MS1-VEGF cells 
after overnight stimulation with either IL-1β or TNF-α.  We stained the activated cells and 
control unstimulated cells for the expression of CD11b, CD31, CD54, CD62P, CD102, and 
CD106 (Figure 2.6).  After overnight stimulation, the cells treated with either IL-1β orTNF-α 
had higher expression of these molecules than the untreated cells.  Also, it appears that 
stimulation with TNF-α induced higher expression of these molecules compared to IL-1β 
stimulation.  Therefore, MS1-VEGF cells, particularly those stimulated with TNF-α, express 
an activated phenotype appropriate for use in a transendothelial migration assay. 
We then wanted to determine which chemokine would be optimal for establishing a 
transendothelial assay.  To do this, we initially set up chemotaxis assays for polarized Tc1 
and Tc2 cells.  Tc1 and Tc2 cells express different chemokine receptors, including CCR5 and 
CCR4, respectively (29, 30).  Studies have shown that Th1 cells migrate more efficiently in 
the presence of MIP-1α compared to Th2 cells (14).  Additionally, MIP-1α has been shown 
to play a role in recruiting CD8+ T cells to tumors (22, 31).  Our lab has previously found 
that transfection of tumor cells with MIP-1α increased tumor infiltration by CD8+ cells and 
that clearance of these tumors was impaired in CD8 knockout mice (22).  Therefore, in order 
to determine the appropriate kinetics for CD8+ T cell migration in our system, we chose to 
examine migration of Tc1 and Tc2 cells in response to the biologically relevant MIP-
1α (Figure 2.7).  We expected that MIP-1α would recruit Tc1 cells more efficiently than Tc2 
cells, and the two cells types could then serve as positive and negative controls, respectively.  
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We titrated the doses of chemokine in the lower well (0ng/mL-100ng/mL) and varied the 
time allowed for migration (4-28h, only 4-12h are shown).  We were able to find migrated 
cells in the lower wells at the earliest time point of 4 hours and many cells had migrated to 
the lower wells at time points 12 hours or later (Figure 2.7 A-C).  However, despite the 
increase in the number of migrated cells over time, we did not observe a chemokine dose-
dependent change in the number of migrated cells.  Thus, it appears that despite numerous 
modifications of kinetics and chemokine concentrations, we were only able to observe 
spontaneous migration of the T cells into lower wells and found no differences between Tc1 
and Tc2 cells in these conditions.  Furthermore, because this chemotaxis assay with polarized 
Tc1 and Tc2 cells needs further modifications before the assay is appropriate for examining 
either chemotaxis or chemotaxis-driven transendothelial migration by these polarized T cells, 
we decided to concentrate our efforts on developing an in vivo system. 
 
GFPxP14 Tc1 and Tc2 cell migration and tumor infiltration in vivo 
 An in vivo model would be ideal, because the models in previous studies suggesting 
that Tc1 and Tc2 cells have different migration properties were tumor therapy models (4, 5, 
11).  We needed a model to examine not only donor cell migration but also tumor infiltration.  
So, we confirmed that the Tc1 and Tc2 cells could be tracked in vivo based on GFP 
expression after transfer into tumor bearing mice.  B6 mice were injected with 1x106 EL-
4.p33 tumor cells s.c. in order to establish tumors.  Then 7 days later, the mice were injected 
with either 1x106 Tc1 or Tc2 cells i.v.  We examined spleen, lymph node, and tumor tissues 
for GFP+CD8+ cells by flow cytomertry on various days after transfer.  We found 
GFP+CD8+ cells in both Tc1 and Tc2 treated mice by day 3 after transfer and continued to 
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find the donor cells on days 6 and 8 after transfer (Figure 2.8-2.11).  Interestingly, we found 
a limited number of donor cells, if any, in the tissues on day 1 and day 10 after transfer, 
suggesting that days 3-8 were the optimal time period for examining Tc1 and Tc2 cells in 
vivo.  Since we established that Tc1 and Tc2 cells derived from GFPxP14 splenocytes were 
tracable in vivo, we proceeded to examine migration and tumor infiltration in vivo (32).  
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Discussion 
Tc1 and Tc2 therapy studies have suggested that Tc1 therapy is more effective than 
Tc2 therapy due to differences in Tc1 and Tc2 migration (4, 5, 11).  Previous studies tracking 
T cells in vivo have utilized a variety of techniques which have limited applications (4, 5, 7-
9, 11-13, 18).  In this study we developed a model utilizing GFP expression of antigen-
specific donor Tc1 and Tc2 cells to examine their migration and tumor infiltration in vivo 
after transfer into tumor bearing mice.  We generated GFPxP14 mice that express both GFP 
and the p33 specific TCR.  T cell populations from these mice maintain GFP expression even 
after stimulation and express the Vβ8 TCR specific for p33 peptide.  Cultured Tc1 and Tc2 
cells derived from GFPxP14 splenocytes express type I and type II cytokine and chemokine 
receptor phenotypes, respectively(29, 30).   When these cultured cells are transferred into 
EL-4.p33 tumor bearing mice, we can identify tumor infiltrating donor CD8+ cells 3 and 7 
days after transfer.  Thus, our GFPxP14 murine model for generating donor cells is a useful 
model for evaluating T cell migration in vivo. 
 This GFPxP14 model has numerous applications.  In vivo imaging is of particular 
interest.  As a new and evolving technique, in vivo imaging is being used by others to 
investigate T cell migration in vivo (18).  Since this technique requires the labeling of the T 
cells, our model is applicable to this technique and is not restricted by the potential loss of T 
cell labeling.  In addition, applying two photon microscropy to the GFPxP14 model will 
allow us to evaluate T cell contact with the other cells in vivo, providing even more details of 
the interaction of the T cells in the tumor mass, as well as transendothelial migration of the 
infiltrating T cells.  These are just two of the additional approaches that can utilize the 
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GFPxP14 model to evaluate T cell migration and tumor infiltration in vivo, including 
polarized donor Tc1 and Tc2 cells.   
As stated previously and described above, an in vivo model is an important tool for 
examining Tc1 and Tc2 cell migration and tumor infiltration, allowing for the complexity of 
an in vivo system (18).  We used our GFPxP14 model to investigate the migration and tumor 
infiltration of Tc1 and Tc2 cells in a subsequent study (32).   However, despite the 
advantages for using an in vivo model, having an in vitro model would allow for future 
studies to contribute to our understanding of the mechanisms of Tc1 and Tc2 cell migration.  
Currently, our in vitro model still requires additional optimizing.  We still need to determine 
the optimal chemokines (type and concentration) to attract Tc1 and Tc2 cells to the lower 
well, as well as the time duration for the assay.  The data do suggest that four hours is too 
short of a time period and that overnight, approximately 18 hours, is possibly too long.  Also, 
we used MIP-1α to attract the Tc1 vs. Tc2 cells to the lower well, based on previous reports 
of Th1 and Th2 chemotaxis and the chemokine receptor expression by the Tc1 and Tc2 cells 
(14, 29, 30).  Because we did not find a dose-dependent migration of neither Tc1 nor Tc2 
cells over time, we believe that we observed only chemokine-independent, spontaneous 
migration.  This may be because, unlike Th1 cells, neither Tc1 nor Tc2 cells respond to MIP-
1α (14). (Perhaps naïve CD8+ T cells would exhibit a chemotactic response.)  It is possible 
that MIP-1α is not the optimal chemokine for attracting polarized CD8+ T cells.  Because 
CXCR3 is expressed by both Tc1 and Tc2 cells, we could use chemokine CXCL11, a ligand 
for CXCR3 that has been implicated in tumor therapy (33).      
Because stimulation of the MS1-VEGF cell line induces an activated phenotype 
appropriate for use in a transendothelial migration assay, we believe that developing a 
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trasnendothelial migration assay with Th1 or Th2 cells would be an important next step 
towards an assay for Tc1 and Tc2 cells using this MS1-VEGF cell line.  Other studies have 
already evaluated Th1 and Th2 cell chemotaxis and transendothelial migration in vitro, so the 
kinetics and optimal chemokines for theTh1 or Th2 cell assay have been determined by 
others (14, 15).  While we were not able to apply these findings directly to Tc1 and Tc2 cells, 
adapting current protocols and using the MS1-VEGF cell line as the source for the 
endothelial cells will allow us to demonstrate whether the MS1-VEGF cell line can be used 
for T cell transendothelial migration assays.  Therefore, we will need to continue to optimize 
this assay before it can be used to compare the migration of Tc1 and Tc2 cells. 
Whether the GFPxP14 model is used for in vitro or in vivo T cell migration, there are 
two key components of our model: antigen specificity and lasting GFP expression of the 
CD8+ T cells.  Antigen-specific T cell receptor transgenic mice are an invaluable tool for 
examining T cell immune responses, because they allow us to investigate the response of a 
monoclonal pool of T cells.  In our model, the T CD8+ T cells are specific for the p33 
antigen, which is expressed by the EL-4.p33 tumor cells (22).  Therefore, we are able to 
examine the response of tumor antigen-specific T cells.  The GFP expression by these T cells 
is critical to our model.  Other methods for tracking donor cells are limited because they 
require antibody staining or cannot track donor cells long-term (18).  Although at least one 
other group has developed a similar GFP model, where the T cells lost GFP expression after 
stimulation, our model is unique in that we have the ability to track our donor cells long-term 
by GFP expression which does not decrease after stimulation (28).  Therefore, our GFPxP14 
model for generating Tc1 and Tc2 cells is an invaluable tool for examining the migration and 










Figure 2.1:  Comparison of B6, P14, and GFPxP14 phenotype.  Thymocytes, splenocytes, 
and lymph node cells from these mice were harvested and stained for CD4, CD8, and Vβ8.  
Expression of these molecules and GFP on lymphocytes in these itssues was determined by 
flow cytometry and are shown in the histograms for B6 (gray line), P14 (dotted black line), 
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Figure 2.2:  Comparison of B6, P14, and GFPxP14 splenocyte cultures.  Splenocytes 
from B6 (light gray histogram), P14 (black histogram), and GFPxP14 (medium gray 
histogram) mice were stimulated with Concanavalin A for 3 days.  The expression of GFP, 
























Figure 2.3:  Phenotype of GFPxP14 Tc1 and Tc2 cultures.  GFPxP14 mice were 
generated by crossing P14 and UBI.GFP mice.  Splenocytes from the GFPxP14 mice were 
stimulated with the addition of p33 peptide and cultured in polarizing conditions for 3 days. 
Histograms in A and B show the expression of GFP and CD8 by lymphocytes in the culture 
and expression of Vβ8 and CD25 by the CD8+ cells, respectively.  Cells from the Tc1 
culture are shown in the filled gray histograms (A-B), while cells from the Tc2 culture are 
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Figure 2.4:  Phenotype of cytokine stimulated MS1-VEGF cells.  Cultured MS1-VEGF 
cells were either unstimulated (cross pattern histogram, top number) or stimulated overnight 
with IL-1β (open histogram, middle number) or TNF-α (dark histogram, bottom number).  
The cells were then stained for the following before being analyzed by flow cytometry: 
CD11b, CD31, CD54, CD62P, CD102, and CD106.  FSCxSSC and isotype control staining 














































Figure 2.5:  Chemotaxis of Tc1 and Tc2 cells in vitro.   1x105 polarized GFPxP14 Tc1 or 
Tc2 cells were added to the upper well of transwell plates with matrigel coated filters (no 
endothelial cells).  MIP-1α (0-100ng/mL) was added to the lower well.  After 4, 8, or 12 















Figure 2.6- Real time RT-PCR analysis of IFNγ, IL-4, CXCR3, CCR4, and CCR5 gene 
expression by Tc1 and Tc2 cell cultures.  mRNA from cells in GFPxP14 Tc1 and Tc2 cell 
cultures were harvested and gene expression was analyzed.  Relative fold expression of 
cytokine and chemokine receptors is expressed relative to Tc1 expression of IL-4, set to a 
value of 1.  Data shown is from one experiment, representing two experiments.  p≤ .05, * or 











Figure 2.7: Tumor growth following transfer of Tc1 or Tc2 cells.  1x106 EL4.p33 tumor 
cells were injected s.c. into B6 mice, followed by an injection of PBS alone or either 1x106 
polarized Tc1 or Tc2 cells.  Tumor growth was assessed every 2-3 days.  Data shown is from 
one experiment, representing at least two experiments.  p≤ .05, * Tc1 vs. PBS control (days 
10, 12, 15, and 18), Tc2 vs. PBS control (days 12, 15, and 18), and Tc1 vs. Tc2 (days 10, 12, 















Figure 2.8:  Donor cells in spleens of Tc1 or Tc2 treated tumor bearing mice. 
On day 0, 1x106 Tc1 (A and B) or Tc2 (C and D) cells generated from GFPxP14 splenocytes 
were transferred i.v. into B6 mice bearing p33.EL-4 s.c. tumors.  On days 1, 3, 6, 8, and 10 
after transfer, splenocytes were harvested, and the cells were stained for CD8.  Lymphocytes 
















Figure 2.9:  Donor cells in contralateral LNs of Tc1 or Tc2 treated tumor bearing mice.  
On day 0, 1x106 Tc1 (A and B) or Tc2 (C and D) cells generated from GFPxP14 splenocytes 
were transferred i.v. into B6 mice bearing p33.EL-4 s.c. tumors.  On days 1, 3, 6, 8, and 10 
after transfer, the contralateral LNs were harvested, and the cells were stained for CD8.  
Lymphocytes were analyzed for GFP and CD8 expression to identify GFP+CD8+ donor cells 

















Figure 2.10:  Donor cells in ipsilateral LNs of Tc1 or Tc2 treated tumor bearing mice.  
On day 0, 1x106 Tc1 (A and B) or Tc2 (C and D) cells generated from GFPxP14 splenocytes 
were transferred i.v. into B6 mice bearing p33.EL-4 s.c. tumors.  On days 1, 3, 6, 8, and 10 
after transfer, ipsilateral LNs were harvested, and the cells were stained for CD8.  
Lymphocytes were analyzed for GFP and CD8 expression to identify GFP+CD8+ donor cells 
















Figure 2.11:  Donor cells in tumors of Tc1 or Tc2 treated tumor bearing mice. 
On day 0, 1x106 Tc1 (A and B) or Tc2 (C and D) cells generated from GFPxP14 splenocytes 
were transferred i.v. into B6 mice bearing p33.EL-4 s.c. tumors.  On days 1, 3, 6, 8, and 10 
after transfer, tumors were harvested, and the cells were stained for CD8.  Lymphocytes were 
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Tc1 cells have been shown to be more effective than Tc2 T cells for adoptive cell 
therapy against tumors.  Differences in migration and tumor infiltration between Tc1 and Tc2 
cells may contribute to this difference in therapeutic efficacy.  In this study we investigated 
migration and tumor infiltration of Tc1 and Tc2 in vivo.  We generated donor cells from 
green fluorescent protein expressing TCR transgenic mice (specific for lymphocytic 
choriomeningitis virus p33 antigen) and investigated the migration and tumor infiltration of 
these cells in mice bearing p33 antigen-negative and p33 antigen-positive tumors.  We report 
that Tc1 cells migrate to TDLNs and infiltrate tumor sites faster and in higher numbers than 
Tc2 cells following injection, regardless of tumor p33 antigen expression.  In vitro and in 
TDLNs, Tc1 cells express significantly higher levels of several adhesion molecules important 
for T cell migration compared to Tc2 cells, specifically CD62L, LFA-1, CD44, and PSGL-1.  
However, we found that all host and donor CD8+ cells infiltrating tumors in Tc1 or Tc2 
treated mice uniformly expressed high levels of LFA-1, CD44, and PSGL-1, regardless of 
tumor expression of p33 antigen.   These results suggest that there is a tumor infiltrating 
phenotype required for CD8+ T cells to migrate to and infiltrate tumor sites; and the higher 
expression of this phenotype by Tc1 cells compared to Tc2 cells contributes to enhanced 
efficiency of Tc1 vs. Tc2 cell migration to TDLNs and infiltration of tumor sites. 
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Introduction 
CD8+ T cells are classified as either type I or type II based on their cytokine secretion 
profile (1).  While Tc1 cells secrete large amounts of IFN-γ, Tc2 cells, in addition to a limited 
amount of IFN-γ, secrete predominantly IL-4, IL-5, and IL-10 (1-6).  Studies have evaluated 
the effectiveness of using in vitro generated Tc1 and Tc2 cells for tumor therapy in order to 
determine if transferred Tc1 or Tc2 cells provide protection against tumor growth or promote 
tumor rejection in tumor-bearing mice (7-18).  In a number of these studies, both Tc1 and 
Tc2 transferred cells were effective in protection against tumor growth, although several 
studies showed that Tc1 therapy was more effective than Tc2 therapy (7-18).   Several 
studies suggested that a possible reason for this difference in therapeutic efficacy was 
differential migration of Tc1 vs. Tc2 cells in vivo, since these studies found more Tc1 cells in 
TDLNs or tumors compared to Tc2 cells after transfer (9, 16).  Conversely, results by others 
showed that there is no difference between the number of Tc1 and Tc2 cells that migrate to 
TDLNs or tumors following injection (10).  Therefore, the efficacy of Tc1 vs. Tc2 cell tumor 
therapy and the efficiency of Tc1 vs. Tc2 cell migration to TDLN and tumor sites are still 
unclear.   
Adhesion molecules such as selectins, integrins, and their ligands play an important 
role in CD8+ T cell migration to lymphoid tissues and infiltration of tumor sites (19-21).  
Molecules such as CD62L,  PSGL-1, LFA-1,  and CD44 have previously been identified as 
adhesion molecules which play a critical role in T cells crossing activated endothelium (22-
25), and several reports suggest they are important for strong anti-tumor responses by 
transferred T cells (26-31).   
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In addition to adhesion molecules, antigen expression by tumor cells has also been 
shown to regulate CD8+ T cell migration and tumor infiltration in vivo (32-35).  A recent 
imaging study showed that more antigen-specific CD8+ T cells were found in the antigen-
positive tumor compared to the antigen-negative tumor within the same animal (35).   
Furthermore, these CD8+ T cells infiltrated further into the tumor mass and were more evenly 
distributed throughout the antigen-positive tumor (35).  Although studies have suggested an 
important role for antigen in CD8+ T cell migration and tumor infiltration, the effect of 
antigen on the migration and tumor infiltration of polarized CD8+ T cells is still unknown.  
In this study, we utilized GFP expression to track donor Tc1 and Tc2 cells in vivo 
during tumor therapy.  We evaluated differences in migration to TDLNs, infiltration of 
established antigen-positive vs. antigen-negative tumors, and expression of adhesion 
molecules by Tc1 and Tc2 cells in vitro and in vivo.  In this study, we report that Tc1 cells 
express a higher level of adhesion molecules than Tc2 cells in vitro following activation and 
in the TDLNs 3 days following transfer in vivo.  Importantly, the adhesion molecule 
phenotype of the tumor infiltrating Tc1 and Tc2 cells is similar, namely PSGL-1 high, LFA-1 
high, and CD44 high, The adhesion molecule phenotype of Tc1 and Tc2 cells was identical 
in antigen-positive vs. antigen-negative tumor sites, despite that antigen does enhance the 
number of Tc1 and Tc2 cells found within the tumor sites.  Overall, this study suggests that 
enhanced expression of adhesion molecules defines a tumor infiltrating phenotype for both 
Tc1 and Tc2 cells, but different expression levels of these adhesion molecules following in 
vitro activation contributes to more abundant migration and tumor infiltration by Tc1 vs. Tc2 
cells in vivo.    
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Materials & Methods 
Mice 
C57BL/6J (B6) and UBI.GFP mice were obtained from The Jackson Laboratory (Bar Harbor, 
Maine) (36).  CD8+ T cell Vβ8 TCR transgenic P14 mice specific for LCMV peptide p33-41 
(KAVYNFATC) in context of H-2Db were originally obtained from Dr. Pam Ohashi (37).  
GFPxP14 mice were generated in our lab by crossing the UBI.GFP strain with the P14 strain 
and using the F1 generation (See Chapter 2).  Spleens of GFPxP14 mice were used as the 
source for our donor cells, as detailed below.  B6 mice were used as recipient animals.  
Female mice aged 8-12 weeks of age were used throughout these experiments.  All mice 
were maintained in specific pathogen free conditions by University of North Carolina’s 
Department of Laboratory Animal Medicine and all animal procedures were approved by the 
university’s Institutional Animal Care and Use Committee.   
 
Tc1/Tc2 cultures 
Tc1 and Tc2 cells were generated in vitro from splenocytes harvested from GFPxP14 mice 
and stimulated at 5x106 cells/mL for 3 days with p33 peptide (KAVYNFATC) along with 2 
units/mL rIL-2 in RPMI medium.  For generating Tc1 cells, we also added rIL-12 at 
12.5ng/mL and anti-IL-4 antibody at 2.5ng/mL, and for generating Tc2 cells we added rIL-4 
at 27.5ng/mL, anti-IL-12 antibody at 5.5ng/mL, and anti-IFN-γ antibody at 5.5ng/mL.  
Recombinant murine cytokines and anti-murine cytokine antibodies were all obtained from 
R&D Systems.   Tc1 and Tc2 cultures were both over 90% GFP+CD8+Vβ8+ after three days 
of culture, as determined by flow cytometry.  Where noted polarized Tc1 or Tc2 cells were 
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restimulated in culture with peptide in identical polarizing conditions for an additional 3 days 
before analysis.  Functional studies confirmed that Tc1 and Tc2 cells generated using this 
protocol proliferate at the same rate and specifically kill p33-loaded targets with equal 
efficiency (38).  Also, we confirmed type-I and type-II cytokine cand chemokine receptor 
gene expression in Tc1 and Tc2 cells generated using this protocol (Figure 2.6).   
 
Tumor cell lines and construction of p33 encoding plasmid 
As a source of antigen-bearing tumor cells, we generated LCMV peptide p33 -expressing 
EL-4 thymoma tumor cells (EL-4.p33β2M cells) (38).  For simplicity, EL-4.p33β2M cells 
are referred to as “p33.EL-4” cells in this publication.  Briefly, EL-4 cells obtained from 
ATCC were transfected with a PcDNA3.0 plasmid (Invitrogen) containing an insert encoding 
the LCMV peptide p33 linked to human beta-2 Microglobulin (38).  Linking peptides to 
human β2 microglobulin has been shown to enhance the peptide presentation in transfected 
cells, evidenced by increased specific lysis compared to target cells transfected with peptide 
alone (39-42).  P33.EL-4 tumor cells were selected and maintained using medium containing 
G418 (Sigma-Aldrich).  Transfection was confirmed by PCR and expression of the p33 
antigen was confirmed by using the transfected cells as targets of P14 T cells in cytolytic 
assays.  Both parental EL-4 (p33 antigen-negative) cells and transfected p33.EL-4 (p33 
antigen-positive) cells were used in this study, as detailed below.   
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Migration and Tumor Infiltration of Tc1 and Tc2 
 5 or 7 days prior to donor cell transfer, B6 mice were injected s.c. in the right ventral flank 
with 1x106-1.5x106 p33.EL-4 tumor cells.  For experiments examining the role of antigen, 
1x106-1.5x106 EL-4 tumor cells were also injected into the mice but into the left ventral flank 
on the same day.  On day 0, 1x106 Tc1 or 1x106 Tc2 donor cells in 200uL of PBS were 
injected i.v. into the tail vein of these mice.  On days 3 and 7 after donor cell transfer, 
TDLNs (axillary and superficial inguinal lymph nodes) and tumors were collected then 
analyzed by flow cytometry.  Four animals were used per treatment group for each time point 
in each experiment.   
 
Flow cytometry analysis of surface molecule expression 
 For cell surface expression analysis, cultured cells or lymph node and tumor tissues were 
harvested.  Tc1 and Tc2 cell cultures were harvested after one or two stimulations.  TDLNs 
and tumors were harvested on days indicated and single-cell suspensions were made.  Cells 
were then stained using monoclonal antibodies (Pharmingen) against the following cell 
surface markers and adhesion molecules important for CD8+ T cell trafficking: CD8, Vβ8, 
CD25, LFA-1, CD44, CD49d, CD62L, PSGL-1, and α4β7 integrin (19-31).  1x105 or 5x105 
cells were analyzed for TDLN and tumor samples, respectively, to allow for comparing 
lymphocyte and total CD8+ cell numbers between samples.  Lymphocytes were gated based 
on forward and side scatter.  Donor and host cells in TDLNs and tumors were identified by 
gating for GFP.  The mean fluorescence intensity (MFI) of surface molecule expression was 
determined in addition to the percent of cells positive for the surface marker.  All flow 
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Experiments were repeated at least twice and data from one representative experiment is 
shown for each figure.  Two-tailed Student’s T-test was utilized to test for significance with p 




Differential Tc1 vs. Tc2 migration to draining lymph nodes and tumor infiltration in vivo 
 We sought to examine Tc1 and Tc2 cell migration and tumor infiltration into 
established p33.EL-4 and EL-4 tumors using GFP expression to track the donor cells.  
UBI.GFP mice (36) were crossed with P14 mice (37) to generate a mouse strain, GFPxP14, 
whose CD8+ T cells express both GFP and the p33-specific TCR from P14 transgenic mice.  
The GFP+ cells from these splenocyte cultures are over 90% CD8+, CD25+, and Vβ8+  
(Figure 2.3).  Tc1 and Tc2 cells were generated from GFPxP14 splenocytes in 3 day cultures 
using polarizing conditions, and then the expression of IFN-γ and IL-4 cytokines as well as 
CXCR3, CCR4, and CCR5 chemokine receptors was examined using real time RT-PCR 
(Figure 2.6).  CXCR3 was expressed similarly by both cultures.  Tc1 cells expressed high 
levels of IFN-γ and CCR5 mRNA expression but low levels of CCR4 with minimal 
expression of IL-4 mRNA, indicative of type I polarization (Figure 2.6).  Tc2 cultures 
exhibited high levels of IL-4 and CCR4 mRNA expression, but relatively low expression of 
IFN-γ and CCR5 mRNA, indicative of type II polarization (Figure 2.6). We also confirmed 
that these in vitro generated Tc1 cells showed significantly higher therapeutic efficacy in 
reducing p33.EL-4 tumor growth than an identical number of in vitro generated Tc2 cells 
injected i.v., while showing no effect on the growth of parental EL-4 cells (Figure 2.7). 
 Tc1 and Tc2 donor cell migration to TDLNs and infiltration of tumor sites was 
evaluated using our p33.EL-4 tumor model.  P33.EL-4 tumors were established in B6 mice 
by injection of 1x106 tumor cells s.c. in the right ventral flank of animals 7 days before the 
injection of in vitro generated Tc1 or Tc2 cells.  This dose established palpable tumors within 
7 days.  On day 0, the animals were injected i.v. with either 1x106 Tc1 or Tc2 donor cells.  
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Then, on days 1, 3, and 7 after therapy, lymph node and tumor tissues were harvested, and 
GFP+ donor and GFP- host cells were examined by flow cytometry.  A limited number of 
GFP+CD8+ cells were found in the TDLNs and at the tumor site in some of the Tc1 treated 
animals, but not in Tc2 treated animals, on day 1 following transfer (Figures 2.10 and 2.11).  
By day 3, a measurable number of GFP+CD8+ cells were found in both Tc1 and Tc2 treated 
mice (Figure 3.1).  More importantly, there were significantly more donor cells in the 
TDLNs and tumors of Tc1 treated mice compared to Tc2 treated mice on both day 3 and day 
7 after transfer (Figure 3.1).   The numbers of lymphocytes and CD8+ cells in Tc1 treated 
mice found in the TDLN or the tumor site were identical to the number found in the same 
sites of Tc2 treated mice on either day 3 or day 7, demonstrating that animals treated with 
Tc1 or Tc2 therapy had similar numbers of total CD8+ T cell migration to TDLN and tumor 
infiltration (Figure 3.1).By day 7, there were more total lymphocytes and total CD8+ cells in 
both TDLNs and tumor sites than on day 3, and the percentage of GFP+ Tc1 and Tc2 donor 
cells increased in both the TDLNs and the tumors sites when compared to the total 
lymphocyte population found in the TDLNs and tumor sites (Figure 3.1).  The number of 
both Tc1 and Tc2 donor cells began to significantly decline after day 7 following transfer 
(Figure 2.11).  These results demonstrate that injection of donor Tc1 or Tc2 cells results in 
their migration to both the TDLN and the tumor site; and the increase in the percentages of 
GFP+ Tc1 and Tc2 donor cells from day 3 to day 7 were not due to a decrease in overall 
lymphocyte or CD8+ cells found at that site.    These results also suggest that the higher 
percentage of Tc1 vs. Tc2 donor cells on both day 3 and day 7 is due to a higher number of 
Tc1 cells within the CD8+ population, rather than increased lymphocyte or total CD8+ cells in 
Tc1 treated animals.  Therefore, it appears that Tc1 cells may migrate more rapidly and in 
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greater numbers to both TDLN and to tumor sites than Tc2 cells following transfer into 
tumor-bearing mice.  
 
Tc1 and Tc2 exhibit a different adhesion phenotype following in vitro activation and in 
TDLN but not in tumor infiltrates 
We examined whether differences between Tc1 and Tc2 cell migration and tumor 
infiltration above were due to differences in adhesion molecule expression by Tc1 and Tc2 
cells.  Monoclonal antibodies to adhesion molecules LFA-1, CD44, CD49d, CD62L, PSGL-
1, and α4β7 integrin were used to phenotype in vitro generated Tc1 and Tc2 cells before 
transfer and at various times after transfer in the TDLN and tumor mass.   GFPxP14 
splenocytes were stimulated with peptide and cultured for 3 days in polarizing conditions, 
then analyzed or restimulated for 3 additional days before analysis by flow cytometry. Tc1 
and Tc2 cells exhibit different profiles of adhesion molecules following one (Figure 3.2A) 
and two (Figure 3.2B) stimulations in vitro.  In particular, it was found that after primary in 
vitro polarization, the level of CD62L and PSGL-1 expression is higher on Tc1 cells than on 
Tc2 cells, while both Tc1 and Tc2 cells expressed comparably high levels of CD44 and LFA-
1 (Figure 3.2A).  More significant differences in Tc1 and Tc2 cell phenotypes were found 
following a second round of in vitro polarization, where Tc1 cells expressed higher levels of 
LFA-1, CD44, CD62L and PSGL-1 (Figure 3.2B),  as well as even stronger polarization to 
the Tc1 or Tc2 phenotype (data not shown).  In contrast, CD49d and α4β7 integrin were only 
minimally expressed by both Tc1 and Tc2 cells, even after the second stimulation (Figure 
3.2B).  Since Tc1 and Tc2 cells express similar levels of CD25 after both primary and 
secondary stimulation, the level of activation does not appear to contribute to the observed 
differences in migration and tumor infiltration (Figure 3.2).    
 79 
 In order to evaluate whether the difference in adhesion phenotype between Tc1 and 
Tc2 donor cells was maintained in vivo and results in differential migration of these cells to 
lymphoid and tumor sites, we examined Tc1 and Tc2 cells from the TDLNs and tumors of 
treated mice on days 3 and 7 after injection.  P33.EL-4 tumor bearing mice were injected 
with 1x106 Tc1 or Tc2 donor cells generated in vitro.  TDLNs and tumors were harvested 
from the mice and the cells were examined for their expression of Vβ8, CD25, LFA-1, 
CD44, CD62L, and PSGL-1 by flow cytometry.  When we examined donor cell phenotypes 
in the TDLN (Figure 3.3), we found that on day 3 Tc1 cells had increased expression of 
CD62L, CD44, PSGL-1, and LFA-1.  However on day 7, only the difference in CD62L 
remained significant (Figure 3.3).  Our results demonstrate that the MFI of CD44, LFA-1, 
and PSGL-1 adhesion molecules was significantly higher on donor Tc1 cells than Tc2 cells 
on day 3 (Figure 3.3A), while on day 7 these differences in expression levels between Tc1 
and Tc2 cells had disappeared (Figure 3.3B).  However, the MFI of CD62L expression was 
significantly higher on Tc1 cells on both day 3 and day 7 (Figures 3.3A and 3.3B) when 
compared to Tc2 cells, suggesting that the higher level of CD62L expression by Tc1 cells 
could contribute to the higher number of Tc1 cells migrating to TDLNs compared to Tc2 
cells.  When activation status for these Tc1 and Tc2 cells was examined, CD25 expression on 
donor cells was low/moderate and Vβ8 expression high (data not shown).  Therefore, the 
overall adhesion phenotype profile of Tc1 vs. Tc2 cells suggests that only a subset of Tc2 
cells have the appropriate expression of adhesion molecules to effectively home to the 
TDLNs following injection.  
We also examined the phenotype of donor cells which had infiltrated into the tumor 
mass on days 3 and 7 following injection.  In contrast to their phenotype in TDLN, the 
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phenotype of both Tc1 and Tc2 cells which had infiltrated the tumors were identical on day 3 
as well as day 7 after injection: They expressed very high levels of CD44, LFA-1, and PSGL-
1 (Figure 3.4)  and moderate levels of CD25 and high Vβ8 (data not shown). When we 
analyzed the phenotype of the host CD8+ cells in the tumors of Tc1 and Tc2 treated mice, we 
found that likewise, these cells expressed the same “tumor infiltrating phenotype”:  LFA-1 
high, CD44 high, and PSGL-1 high (data not shown).  This data supports that in order for 
cells to infiltrate a tumor, they must express a high level of certain adhesion molecules 
necessary for transendothelial migration, and that a much smaller number of Tc2 cells 
express the appropriate phenotype needed to infiltrate into tumors when compared to Tc1 
cells.  Therefore, it appears that the ability of Tc1 cells to migrate to tumor sites more 
efficiently than Tc2 cells may be due to their inherent ability to express higher levels of 
adhesion molecules critical for tumor infiltration.   
 
The role of antigen in Tc1 and Tc2 migration and tumor infiltration  
 Presentation of antigen by tumor cells and/or APC and the recognition of this antigen 
by antigen-specific T cells plays an important role in regulating CD8+ T cell trafficking (32-
35), so we evaluated the migration to and infiltration of antigen-positive and antigen negative 
tumors by p33-specific Tc1 vs. Tc2 cells.   B6 mice were injected s.c. with EL-4 (left flank) 
and p33.EL-4 (right flank) tumor cells and after 7 days, Tc1 or Tc2 donor cells were injected 
i.v. and TDLNs and tumor infiltration were analyzed by flow cytometry.  As expected, there 
were a larger number of both Tc1 and Tc2 cells in the p33.EL-4 tumor compared to the EL-4 
tumor on day 3, while we found that by day 7, the number of Tc1 cells infiltrating the EL-4 
tumor was equivalent to the number found in the p33.EL-4 tumors (Figure 3.5).  We also 
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found that there continued to be more Tc1 cells migrating to both the p33.EL-4 and the EL-4 
tumor sites than Tc2 on both days 3 and 7, suggesting that antigen expression at the site of 
the tumor mass does not play a role in the preferential migration of antigen-specific Tc1 cells 
to tumor sites, or on the kinetics of their migration (Figure 3.5).     
We next evaluated the tumor-infiltrating phenotype of Tc1 and Tc2 cells infiltrating 
both p33.EL-4 and EL-4 tumors by looking at the cell surface expression of LFA-1, CD44, 
and PSGL-1.  Surprisingly, we found no significant differences in the MFI of these adhesion 
molecules for both Tc1 and Tc2 cells in antigen-positive p33.EL-4 vs. antigen-negative EL-4 
tumors (Figure 3.6), namely they were LFA-1, CD44, and PSGL-1 high.  Likewise, host cells 
that migrate into both p33.EL-4 and EL-4 tumors following injection of either Tc1 or Tc2 
cells expressed this identical phenotype (3.7), indicating again that there is a tumor-
infiltrating phenotype that dictates whether cells can infiltrate tumors.  These data suggest 
that while antigen may play a role in increasing the amount of cellular infiltrate for both Tc1 
and Tc2 donor cells, it does not play a role in the kinetics of infiltration, the tumor-infiltrating 
phenotype of CD8+ T cells, or the preferential migration of Tc1 cells to tumor cells following 
injection.     
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Discussion 
 In this study, we examined migration and tumor infiltration of Tc1 and Tc2 by 
transferring GFP-expressing p33-specific donor cells into tumor bearing mice.  When we 
examined the migration to TDLNs and infiltration into tumors, we found more Tc1 cells than 
Tc2 cells at both sites on days 3 and 7 after transfer.  We also found that while Tc1 and Tc2 
cells have different adhesion molecule profiles in vitro following antigenic stimulation and in 
TDLNs following injection, the donor Tc1 and Tc2 cells that infiltrate the tumor have 
identical expression of adhesion molecules regardless of the time we examined them or 
whether or not these tumors express p33 antigen.  Moreover, host cells infiltrating tumors 
also express this identical phenotype-- high levels of LFA-1, CD44, and PSGL-1 expression.  
Therefore, it appears that the selective advantage of Tc1 cells to migrate to and infiltrate 
tumor sites appears to be due to their intrinsically higher expression of several adhesion 
molecules critical for tumor infiltration, and this expression does not appear to be altered by 
the presence of antigen at the tumor site.  These results suggest that tumor infiltration by 
activated CD8+ T cells requires the expression of a “tumor infiltrating phenotype”, and that 
Tc1 cells generated in vitro naturally express this phenotype (which is characterized by a 
high expression level of LFA-1, CD44, and PSGL-1) more abundantly than Tc2 cells.    
 Our extensive analysis of adhesion molecule phenotypes suggests a critical role for 
LFA-1, CD44, and PSGL-1 in the differences in tumor infiltration we see between Tc1 and 
Tc2 cells.  Our results demonstrate that Tc1 and Tc2 cells infiltrating the tumors on days 3 
and 7 have similar adhesion profiles, a “tumor infiltrating phenotype” that is LFA-1 high, 
CD44 high, and PSGL-1 high.  This phenotype is expressed by a greater number of Tc1 vs. 
Tc2 cells following in vitro activation and at TDLNs on day 3, which may promote earlier 
 83 
and more effective tumor infiltration by Tc1 cells compared to Tc2 cells.  The existence of a 
“tumor infiltrating phenotype” is supported by previous findings suggesting a role for CD44, 
LFA-1, and PSGL-1 in CD8+ T cell-mediated tumor rejection (26-31).  Although 
requirement of these specific adhesion molecules for tumor infiltration has not yet been 
demonstrated, our results indicate that high expression of CD44, LFA-1 and PSGL-1 may 
play a critical role in tumor infiltration.    
 Another important consideration for differences in T cell migration is the 
effector/memory phenotype of the cells, which is indicated in part by CD44 as well as 
CD62L expression (19-21, 30, 43-46).  Importantly, CD62LhighCD44high cells have been 
shown to be more effective in tumor therapy than CD62LlowCD44high cells, possibly due to 
the cells trafficking through TDLNs (30, 43-46).  CD44 is upregulated on effector T cells as 
well as both effector and central memory T cells (TEM and TCM, respectively), while CD62L 
is expressed on naïve T cells and only TCM (19-21, 43-46).  We and others find CD62L 
expression is also higher for Tc1 cells than Tc2 cells following activation (10), indicating 
that Tc1 cultures may contain more cells with the TCM phenotype (CD62LhighCD44high ) 
compared to Tc2 cultures that have more cells with the TEM phenotype (CD62LlowCD44high).  
Since CD62L is important for homing to lymph nodes (19-21, 25), the higher level of CD62L 
expression by Tc1 cells vs. Tc2 cells in vitro and in vivo could contribute to the increased 
migration of Tc1 cells to TDLNs compared to Tc2 cells in vivo.  Lower expression of CD62L 
by Tc2 cells may also contribute to the limited anti-tumor function of Tc2 cells observed in 
vivo.   
 While previous studies have reported higher numbers of CD8+ T cell infiltrating 
further into antigen-positive vs. antigen-negative tumors (34, 35), the role of antigen 
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expression by tumor endothelium in promoting CD8+ T cell infiltration remains unclear.  In 
particular, whether antigen expression on tumors impacts Tc1 and Tc2 cell tumor infiltration 
is undefined.   Interestingly, we found that while the number of both donor Tc1 and Tc2 cells 
was higher in antigen-positive tumors compared to antigen-negative tumors, the expression 
of antigen did not appear to affect any of the following: the kinetics of donor cell infiltration; 
the enhanced infiltration of tumors by Tc1 cells compared to Tc2 cells; or the adhesion 
phenotype profiles of the infiltrating Tc1 and Tc2 donor cells.  The Tc1 and Tc2 cells, as 
well as host CD8+ T cells, in both the antigen-positive and antigen-negative tumors all 
expressed the same LFA-1highCD44highPSGL-1high “tumor infiltrating phenotype”.  Since Tc1, 
Tc2, and host CD8+ T cells within the p33.EL-4 and EL-4 tumors express this phenotype, the 
role of antigen expression by tumors may be to simply expand the population of cells 
responding to the tumor.  However, because antigen presentation does alter the expression of 
these adhesion molecules on CD8+ T cells (19-25), the enhanced infiltration by Tc1 and Tc2 
cells to antigen-positive tumors may also be due to differences in either adhesion molecule 
distribution or altered conformation (22-25).   
 In summary, this study shows evidence of migration and tumor infiltration differences 
between Tc1 and Tc2 cells.  Tc1 cells migrate to TDLNs and infiltrate tumors more 
efficiently than Tc2 cells.  Adhesion molecule profiles of Tc1 and Tc2 cells in vitro prior to 
transfer suggest that the enhanced efficiency of Tc1 cell migration and infiltration compared 
to Tc2 cells is due to increased expression of CD62L and an LFA-1highCD44highPSGL-1high 
tumor infiltrating phenotype.  Tc1 and Tc2 cells in the antigen-negative tumors express this 
phenotype, and Tc1 cells infiltrate these tumors in higher number than Tc2 cells.  This 
suggests that the intrinsic differences in adhesion molecule expression between Tc1 and Tc2 
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cells before transfer contributes to antigen-independent trafficking of the antigen-specific 
Tc1 and Tc2 cells into tumors.  Therefore, Tc1 cells are recommended for adoptive cell 
therapy, due to their high expression of a tumor infiltrating phenotype and superior migration 









Figure 3.1:  Tc1 and Tc2 donor cell migration to TDLNs and infiltration of tumors in 
vivo.    On day 0, 1x106 Tc1 (A and B) or Tc2 (C and D) cells generated from GFPxP14 
splenocytes were transferred i.v. into B6 mice bearing p33.EL-4 s.c. tumors.  On days 3 and 
7 after transfer, TDLNs and tumors were harvested, and the cells were stained for CD8.  
Lymphocytes were analyzed for GFP and CD8 expression to identify GFP+CD8+ donor cells 
using FlowJo.  A and C show dot plots of GFP and CD8 staining from one of four animals in 
each group.  B and D show collective data from all four animals in each group.  Data shown 
represent two experiments. ** p≤.01 Tc1 vs. Tc2 cells on day 3 and day 7 in TDLNs.  

























Figure 3.2:  Phenotype of Tc1 and Tc2 cells in vitro.  Tc1 (black line) and Tc2 (grey line) 
cells were stained for the expression of CD25, LFA-1, CD44, CD49d, CD62L, PSGL-1, and 
α4β7 integrin on day three of culture (A) and after three days of restimulation in vitro (B).  
Staining for expression was analyzed using FlowJo. 
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Figure 3.3:  Phenotype of Tc1 and Tc2 cells in TDLNs 3 and 7 days after transfer into 
mice with established tumors. On day 0, 1x10^6 Tc1 or Tc2 cells generated in vitro from 
GFPxP14 splenocytes were transferred i.v. into B6 mice bearing p33.EL-4 tumors.  On days 
3 (A) and 7 (B) after transfer, TDLNs were harvested and stained for CD8, CD62L, CD44, 
LFA-1, and PSGL-1 expression.  GFP+CD8+ lymphocyte Tc1 (open bars) and Tc2 (shaded 
bars) cells were gated and analyzed for MFI of adhesion molecule expression using FlowJo.  
Data shown is from four animals per group and is representative of two experiments.  * p≤.05 
Tc1 vs. Tc2 expression of CD25, CD62L, CD44, LFA-1, and PSGL-1 on day 3.  *p≤.05 Tc1 
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Figure 3.4:  Phenotype of Tc1 and Tc2 in tumors 3 and 7 days after transfer into mice 
with established tumors.  1x106 Tc1 or 1x106 Tc2 cells generated in vitro from GFPxP14 
splenocytes were transferred i.v. into B6 mice bearing p33.EL-4 tumors.  On days 3 (A) and 
7 (B) after transfer, tumors were harvested and stained for the following markers:  CD8, 
CD44, LFA-1, and PSGL-1.  Tc1 (open bars) and Tc2 (shaded bars) cells were gated based 
on GFP+CD8+ expression and the MFI of staining for both populations was analyzed using 
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Figure 3.5:  Tc1 and Tc2 cell migration to TDLNs and tumor sites of antigen-positive 
and antigen-negative tumors.  On day 0, 1x106  Tc1 (A) or Tc2 (B) cells generated from 
GFPxP14 splenocytes were transferred i.v. into B6 mice bearing EL-4 (left flank) and 
p33.EL-4 (right flank) s.c. tumors.  On days 3 and 7 after transfer, TDLNs and tumors were 
harvested, and the cells were stained for CD8.  Lymphocytes were analyzed for GFP and 
CD8 expression to identify GFP+CD8+ donor cells using FlowJo.  Data shown is from four 
animals per group and is representative of two experiments. * p≤.05 Tc1 cells in EL-4 vs. 
p33.EL-4 TDLNs on day 7 and tumors on day 3 after transfer.  *p≤.05 Tc2 cells in EL-4 vs. 














































Figure 3.6:  Phenotype of Tc1 and Tc2 cells in antigen-positive vs. antigen-negative 
tumors.  On day 0, 1x106 Tc1 or Tc2 cells generated from GFPxP14 splenocytes were 
transferred i.v. into B6 mice bearing EL-4 (left flank) and p33.EL-4 (right flank) s.c. tumors.  
On days 3 (A) and 7 (B) after transfer, tumors were harvested, and the cells were stained for 
CD8, CD44, LFA-1, and PSGL-1.  GFP+CD8+ donor lymphocytes were gated and analyzed 
for adhesion molecule expression using FlowJo.  Data shown is from four animals per group 













































Figure 3.7:  Phenotype of host CD8+ cells in antigen-positive vs. antigen-negative 
tumors in Tc1 or Tc2 treated animals.  On day 0, 1x106 Tc1 or Tc2 cells generated from 
GFPxP14 splenocytes were transferred i.v. into B6 mice bearing EL-4 (left flank) and 
p33.EL-4 (right flank) s.c. tumors.  On days 3 (A) and 7 (B) after transfer, tumors were 
harvested, and the cells were stained for CD8, CD44, LFA-1, and PSGL-1.  GFP-CD8+ host 
lymphocytes were gated and analyzed for adhesion molecule expression using FlowJo.  Data 
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Chapter IV 
Gene Expression in Donor and Host Cell in Tc1 and Tc2 Treated Animals 






Previously, we demonstrated that Tc1 and Tc2 cells have different migration and 
tumor infiltration properties in vivo.  In addition, we found that CD8+ cells in tumors of Tc1 
and Tc2 treated animals express a “tumor infiltrating phenotype” characterized by expression 
of specific adhesion molecules such as PSGL-1.  It is unknown how PSGL-1 protein levels 
are regulated in CD8+ T cells.  In the following preliminary study, we used real time RT-
PCR to evaluate whether molecules implicated in the regulation of PSGL-1 in CD4+ T cells 
(T-bet, selectin glycosylating enzymes, and PSGL-1) are also involved in the regulation of 
PSGL-1 in CD8+ T cells.  We examined the gene expression of  CD43, another selectin 
ligand believed to be regulated by T-bet and glycosylating enzymes.  We found that T-bet 
and CD43 genes are significantly higher in Tc1 cells compared to Tc2 cells, which suggest 
that T-bet may have a role in the regulation of a Tc1 vs. Tc2 phentoype.  mRNA levels of 
PSGL-1 and the glycosylating enzymes were similar in both Tc1 and Tc2 cells, suggesting 
that differences in cell surface levels of PSGL-1 protein by Tc1 vs. Tc2 cells is not due to 
differences in the transcription of genes for these molecules.  Migration is also regulated by 
chemokines such as IP-10, MDC, and MIP-1α, whose receptors, CXCR3, CCR4, and CCR5, 
are differentially expressed by Tc1 and Tc2 cells.  We evaluated gene expression of these 
chemokines and chemokine receptors in Tc1 and Tc2 treated animals by real time RT-PCR.  
We found that IP-10 was highly expressed in tumors of both Tc1 and Tc2 treated animals 
compared to MDC and MIP-1α.  We also found that tumor infiltrating host and donor CD8+ 
cells expressed high levels of CXCR3 and IFN-γ, indicating that tumor infiltrating cells 
express a type I phenotype.      
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Introduction 
As described earlier, T cell migration is regulated by molecules important for 
adhesion and chemotaxis (See Chapter 1) (1-4).  We and others have found that Tc1 and Tc2 
cells have different expression profiles of these molecules, and studies have also suggested 
that Tc1 and Tc2 cells have different migration properties (Figures 2.6 and 3.2-3.4) (5-8).  
We found that Tc1 cells migrate to TDLNs and infiltrate tumors more efficiently than Tc2 
cells (Figure 3.1).  We also found that Tc1 cells had higher cell surface levels of adhesion 
molecules in vitro compared to Tc2 cells (Figure 3.2).  The differences in adhesion molecule 
cell surface expression likely play a role in the migration differences observed between Tc1 
and Tc2 cells in vivo.  However, it is not clear how these adhesion molecules are regulated 
differently in Tc1 and Tc2 cells. 
One of the adhesion molecules Tc1 cells express more than Tc2 cells on the cell 
surface is PSGL-1 (Figure 3.2) (9).  Expression of PSGL-1 is regulated both at the level of 
gene expression and post-translational modification of the core protein by glycosylating 
enzymes (9).  PSGL-1 gene expression is believed to be under the control of transcription 
factor T-bet and its associated signaling molecules (10-12).  Interestingly, T-bet is expressed 
in Th1 but not Th2 cells, suggesting that T-bet may be a type I specific transcription factor 
(11-13).  Despite confirmed expression of T-bet by CD8+ T cells, expression of T-bet has not 
yet been confirmed in polarized Tc1 or Tc2 cells (10).  T cells from T-bet knockout mice 
exhibit impaired transendothelial migration in vitro that is restored by forced expression of 
T-bet (11, 12).  This is thought to be due to the decreased level of selectin ligand synthesis in 
T-bet knockout cells, because T-bet has been shown to regulate expression of glycosylating 
enzymes critical for selectin ligand synthesis (11, 12).  These enzymes include α1,3-
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fucosyltransferase-VII (FucT-VII), β1,4-galactosyltransferase-I (B4GalT-I), sialyl 
transferase-IV (ST3GalT-IV), sialyltransferase-VI (ST3GalT-VI), and β1,6-
glucosaminyltransferase-I (C2GlcNAcT-I) (8, 11, and 12).  In order to examine the 
mechanism of PSGL-1 regulation in Tc1 and Tc2 cells, we evaluated the gene expression of 
PSGL-1 itself, as well as T-bet and the glycosylating enzymes, in both Tc1 and Tc2 cells 
polarized in vitro. 
While adhesion molecules are important for infiltration of tumors, chemokines and 
the expression of the appropriate chemokine receptors by T cells are important for migration 
of T cells to the tumor site (1-4).  Tc1 and Tc2 cells express different levels of chemokine 
receptors, and therefore are likely to migrate in response to different chemokines (5).  Tc1 
cells express CCR5 and CXCR3, while Tc2 cells express CCR4 and CXCR3 (Figure 2.6) (5).  
The different expression of chemokine receptors may play a role in the different migration 
efficencies of Tc1 and Tc2 cells that we observed in vivo (Figure 3.1).  Chemokines such as 
IP-10, MDC, and MIP-1α bind to CXCR3, CCR4, and CCR5, respectively (14-19).  Tc1 
therapy has been shown to promote upregulation of chemokines in treated animals compared 
to untreated animals (20).  Differences in chemokine expression in Tc1 vs. Tc2 treated 
animals may also play a role in the different migration efficencies of Tc1 and Tc2 cells, as 
well as the different therapeutic effectiveness of Tc1 and Tc2 therapies.  For these reasons, 
we examined the expression of these chemokines in tumors of Tc1 vs. Tc2 treated mice and 
the expression of these chemokine receptors by Tc1 and Tc2 cells in TDLNs and tumors after 
transfer.   
In following preliminary studies, we evaluated gene expression by donor Tc1 and Tc2 
cells in vitro and by host and donor cells in vivo after ACT therapy using real time RT-PCR .  
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We found that T-bet is expressed higher in Tc1 vs. Tc2 cells, and that PSGL-1 mRNA levels 
are similar between Tc1 and Tc2 cells.  Glycosylating enzymes were also expressed similarly 
between Tc1 and Tc2 cells.  CD43, another selectin ligand which may be under control of T-
bet, was also expressed higher in Tc1 compared to Tc2 cells (9-12).  The chemokine IP-10, 
that binds CXCR3, was expressed higher than either MIP-1α or MDC in tumors of Tc1 and 
Tc2 treated animals.  IP-10 expression was similar between Tc1 and Tc2 treated animals on 
day 3 but significantly higher in Tc1 treated animals on day 7.  CXCR3 was also the highest 
expressed chemokine receptor by host cells in tumors of Tc1 and Tc2 treated animals.  
CXCR3 was expressed by both Tc1 and Tc2 cells in the tumors on day 3 and 7 after transfer, 
but Tc1 cells expressed significantly higher levels of CXCR3 gene on day 7.  We examined 
whether Tc1 and Tc2 donor cells are still polarized in TDLNs and tumors after transfer by 
evaluating IFN-γ and IL-4 expression in addition to the chemokine receptors CXCR3, CCR4, 
and CCR5.  Donor cells in the tumors expressed IFN−γ on day 3 after transfer, and only Tc1 
cells expressed IFN−γ on day 7 after transfer.  Neither Tc1 nor Tc2 cells in the tumors on 
days 3 or 7 expressed IL-4.   In addition we evaluated gene expression in host cells, and we 
found that like donor cells, host cells in tumors expressed IFN-γ but not IL-4 after donor cell 




 C57BL/6J (B6) and UBI.GFP mice were obtained from The Jackson Laboratory (Bar 
Harbor, Maine) (21).  CD8 T cell vβ8 TCR transgenic P14 mice specific for LCMV peptide 
p33-41 (KAVYNFATC) in context of H-2Db were originally obtained from Dr. Pam Ohashi 
(22).  GFPxP14 mice were generated in our lab by crossing the UBI.GFP strain with the P14 
strain and using the F1 generation (See Chapter 2).  Splenocytes of these GFPxP14 mice 
were used as the source for our donor cells, as detailed below.  B6 mice were used as 
recipient animals.  Female mice aged 8-12 weeks of age were used throughout these 
experiments.  All mice were maintained in specific pathogen free conditions by University of 
North Carolina’s Department of Laboratory Animal Medicine and all animal procedures 
were approved by the university’s Institutional Animal Care and Use Committee.   
 
Tc1/Tc2 cultures 
 Splenocytes from GFPxP14 mice were harvested and then stimulated at 5x106 cells/ml for 3 
days with p33 peptide (KAVYNFATC) along with 2 units/mL rIL-2 in RPMI medium.  For 
Tc1 cells, we also added rIL-12 at 12.5ng/mL and anti-IL-4 antibody at 2.5ng/mL, but for 
Tc2 cells we added rIL-4 at 27.5ng/mL, anti-IL-12 antibody at 5.5ng/mL, and anti-IFN-γ 
antibody at 5.5ng/mL.  Recombinant murine cytokines and anti-murine cytokine antibodies 
were all obtained from R&D Systems.   After 3 days in culture, Tc1 and Tc2 cells were either 




Tumor cell lines and construction of p33 encoding plasmid 
As a source of antigen-bearing tumor cells, our lab has previously generated LCMV peptide 
p33 -expressing EL4 thymoma tumor cells (EL-4.p33 cells, 23)  Briefly, EL4 cells obtained 
from ATCC were transfected with a PcDNA3.0 plasmid (Invitrogen) containing an insert 
encoding the LCMV peptide p33 linked to human beta 2 microglobulin (23).  P33.EL4 tumor 
cells were selected and maintained using RPMI-1640 medium containing G418 (Sigma-
Aldrich).  Transfection was confirmed by PCR and expression of the p33 antigen was 
confirmed by using the transfected cells as targets of P14 T cells in cytolytic assays (23).  
Both parental EL4 (p33 antigen-negative) cells and transfected p33.EL4 (p33 antigen-
positive) cells were used in this study, as detailed below.   
 
Real Time RT- PCR 
Cells from Tc1 and Tc2 cultures were analyzed for expression of numerous genes: IFN-γ, IL-
4, CXCR3, CCR4, CCR5, T-bet, PSGL-1, CD43, FucT-VII, B4GalT-I, ST3GalT-IV, 
ST3GalT-VI, and C2GlcNAcT-I.  Sorted donor GFP+CD8+ and host GFP-CD8+ cells from 
Tc1 and Tc2 treated mice were analyzed on days 3 and 7 after transfer for expression of IFN-
γ, IL-4, CXCR3, CCR4, and CCR5.  These cells were sorted using a MoFlo flowcytometer 
from Cytomation.  Tumors from Tc1 and Tc2 treated mice on days 3 and 7 after transfer of 
donor cells were analyzed for expression of MIP-1α, MDC, and IP-10.  mRNA expression 
various genes was examined using TaqMan Gene Expression Assays from Applied 
Biosystems.  Total RNA was isolated from in vitro and in vivo samples using RNEasy 
Minikits from Qiagen followed by DNase I treatment (Promega).  mRNA was converted to 
cDNA using Superscript III (Invitrogen).  This cDNA was then used in Real Time PCR 
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reactions using an ABI 7700 thermocycler.  Samples were run in triplicate.  Data was 
analyzed according to the methods of Livak and Schmittgen (24).  Ct values for the cytokine 
and chemokine receptor genes were normalized to GAPDH expression for the same mRNA 
source.  The lowest level of specific gene expression by a sample was set to a value of 1.00, 




Experiments have not yet been repeated and therefore data from one experiment is shown for 
each figure.  Four animals were used per group for each time point in each experiment and 
cells from these animals were pooled to make one representative mRNA source.  Two-tailed 
Student’s T-test was utilized to test for significance with p ≤.05 considered significant. 
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Results 
Gene expression of T-bet and genes regulating selectin ligand synthesis 
 Previously we found that PSGL-1 is more highly expressed on the cell surface of Tc1 
than Tc2 cells, as determined by flow cytometry (Figure 3.2).  Because molecules important 
for surface expression of PSGL-1 expression have been identified in Th1 cells, we evaluated 
the expression of these genes in Tc1 and Tc2 cells (9, 11, 12).  We harvested RNA from 
cultured GFPxP14 splenocyte derived Tc1 and Tc2 cells on day 3 of culture.  We then used 
real time RT-PCR to evaluate the mRNA expression of the following genes: PSGL-1 itself, 
T-bet (transcription factor known to modulate PSGL-1 in Th1 cells), CD43 (another selectin 
ligand thought to be modulated by T-bet), and the glycosylating enzymes FucT-VII, B4GalT-
I, ST3GalT-IV, ST3GalT-VI, and C2GlcNAcT-I (9-12).  Expression of these genes was 
compared to IFN-γ and IL-4 expression by the Tc1 and Tc2 cells. 
 We first confirmed that the cells from the Tc1 culture were polarized, expressing a 
significantly higher level of IFN-γ and significantly lower level of IL-4 gene expression 
compared to Tc2 cells (Figure 4.1).  As expected from previous studies in Th1 vs. Th2 cells, 
Tc1 cells express significantly higher levels of T-bet compared to Tc2 cells (Figure 4.1) (10- 
13).  Despite the higher level of PSGL-1 on the surface of Tc1 vs. Tc2 cells we observed 
previously, we found no significant difference between the gene expression of PSGL-1 or the 
glysosylating enzymes between Tc1 and Tc2 cells (Figure 4.1).  In contrast, we did find a 
significant difference in the gene expression of CD43, which is thought to be regulated 
similarly to PSGL-1 in Th1 cells (Figure 4.1) (11, 12). This suggests that the higher PSGL-1 
expression in Tc1 vs. Tc2 cells is not due to differences in the mRNA level of PSGL-1 or the 
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glycosylating enzymes we examined.  Our data also suggest that indeed, T-bet may be an 
important transcription factor contributing to the Tc1 vs. Tc2 phenotype.   
 
Chemokine gene expression by tumors in Tc1 and Tc2 treated animals 
 Once we had briefly examined gene expression, which may contribute to the different 
level of PSGL-1 on Tc1 and Tc2 cells, we then began to evaluate whether expression of 
chemokines and their receptors may have contributed to the differences in Tc1 and Tc2 
migration.  Because Tc1 therapy has been shown to increase IP-10 chemokine production 
compared to no treatement, we evaluated chemokine expression by cells in tumors of Tc1 
and Tc2 treated animals (Figure 4.2) (20).  We chose to examine the gene expression of IP-
10, MDC, and MIP-1α, which can bind chemokine receptors CXCR3, CCR4, and CCR5, 
respectively (1-5, 14-19).  These chemokine receptors are differentially expressed on Tc1 and 
Tc2 cells (Figure 2.6) (5).   We found no difference in MIP-1α expression between Tc1 and 
Tc2 treated animals on either day 3 or 7 after donor cell transfer (Figure 4.2).  We also found 
no difference the expression of MDC or IP-10 in Tc1 vs. Tc2 treated animals on day 3 after 
transfer (Figure 4.2).  However, we did find significantly higher expression of both MDC and 
IP-10 by cells in the tumors of Tc1 vs. Tc2 treated animals on day 7 after donor cell transfer 
(Figure 4.2).  Importantly, IP-10 was expressed significantly higher than either MIP-1α or 
MDC at each time point in both Tc1 and Tc2 treated animals (Figure 4.2).  Therefore, these 
data suggest that MDC expression may be induced following Tc1 treatement, but both Tc1 
and Tc2 treatment may induce significant expression of IP-10, particularly on day 7 in Tc1 
treated animals.   
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Cytokine gene expression of donor cells and host cells in Tc1 and Tc2 treated animals 
 Cytokine signaling can upregulate the expression of chemokines (e.g. IFN-γ induces 
IP-10) (4, 14-19).  Therefore, although we had previously shown that the Tc1 and Tc2 cells 
were distinctly polarized populations in vitro (Figure 2.6), we examined whether the 
transferred donor cells maintained the Tc1 and Tc2 cytokine profile in vivo.  We compared 
IFN−γ and IL-4 gene expression of donor cells in TDLNs and tumors in order to evaluate the 
maintenance of donor cell polarization after transfer (Figures 4.3).  This also allowed us to 
evaluate whether Tc1 donor cells may continue to express more IFN-γ in vivo after transfer 
compared to Tc2 cells, which could promote the increased level of IP-10 production in the 
tumors of Tc1 vs. Tc2 treated animals on day 7, as seen above (Figure 4.2).  We found that 
on days 3 in TDLNs, both Tc1 and Tc2 cells had the appropriate levels of IFN-γ to indicate 
type I (high IFN-γ) and type II (low IFN-γ) polarization, respectively (Figure 4.3).  IL-4 was 
expressed minimally by both Tc1 and Tc2 donor cells on day 3.  In contrast on day 7, not 
only did Tc2 donor cells express higher amounts of IFN-γ that were comparable to Tc1 cell 
IFN-γ gene exprsesion, but also, the Tc2 cell expression of IL-4 was not detected (Figure 
4.3).  (IL-4 was also not detected in Tc1 cells on day 7.(Figure 4.3))   When we examined the 
donor cells in tumors on day 3, we found that Tc1 cells have higher expression of IFN-γ 
compared to Tc2 cells, indicative of type I and type II polarization (Figure 4.3).  On day 7 in 
the tumors, Tc1 donor cells had less IFN-γ expression than on day 3 after transfer, but Tc2 
donor cells had no detectable expression of IFN-γ (Figure 4.3).  Neither donor cell population 
expressed IL-4 on day 3 or day 7 after transfer (Figure 4.3).  Therefore, these data suggest 
that while the Tc2 cells may convert to a type I phenotype in the TDLNS, still expressing 
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IFN−γ on day 7 and no IL-4, Tc2 cells may ultimately down-regulate cytokine gene 
expression at the tumor sites, not expressing IFN−γ or IL-4. 
 Cytokine production by Tc1 and Tc2 donor cells has been shown to be important for 
host responses, which are predominantly type I responses (20, 25-28).  Therefore, because 
cytokine signaling promotes T cell polarization, we compared gene expression of IFN-γ and 
IL-4 by host CD8+ cells in Tc1 and Tc2 treated mice (Figure 4.4).  The profile of higher 
IFN-γ vs. low/undetectable IL-4 expression in the host cells from both Tc1 and Tc2 treated 
animals suggests that host cells exhibit a type I phenotype in the TDLNs and tumors (Figure 
4.4).  In TDLNs IFN-γ was more highly expressed than IL-4 in host cells from Tc1 and Tc2 
treated animlas on days 3 and 7 after donor cell transfer (Figure 4.4).  Expression of IFN−γ in 
host cells of Tc1 treated animals was significantly higher on day 3 compared to host cells of 
Tc2 treated animals (Figure 4.4).  IL-4 expression was barely detectable in host cells of both 
Tc1 and Tc2 treated animals in the TDLNs (Figure 4.4).  In tumors IFN-γ was more highly 
expressed by host cells from Tc1 vs. Tc2 treated animals on day 3, but was expressed 
similarly by host cells from both treatement groups on day 7 (Figure 4.4).  IL-4 was 
undetected at both time points in both treatment groups (Figure 4.4).  Therefore, it appears 
that host CD8+ cells in both Tc1 and Tc2 treated animals exhibit a predominant type I 
phenotype, based on their cytokine gene expression in TDLNs and tumors.   
 
Chemokine Receptor gene expression of donor cells and host cells in Tc1 and Tc2 treated 
animals 
 Simialry to cytokine expression, chemokine receptor expression is also an indicator of 
type I or type II polarization (5).  Since we had observed differences in the level of 
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chemokine receptor expression by Tc1 and Tc2 cells (Figure 2.6) and differences in the 
expression of chemokines by tumors in Tc1 vs. Tc2 treated animals (Figure 4.2), we 
evaluated the expression of CXCR3, CCR4, and CCR5 chemokine receptors by donor and 
host CD8+ cells in TDLNs and tumors on days 3 and 7 after donor cell transfer (Figures 4.5 
and 4.6).  In TDLNs CXCR3 expression by Tc1 and Tc2 cells was higher than expression of 
CCR4 or CCR5 (Figure 4.5).  Tc1 and Tc2 cells expressed similar levels of CXCR3 on day 3 
after transfer, but Tc1 cells expressed significantly higher levels of CXCR3 expression on 
day 7 (Figure 4.5).  CCR4 was minimally expressed by both Tc1 and Tc2 cells on day 3 after 
transfer, but only minimally detectable in Tc1 cells on day 7 (not detectable in Tc2 cells on 
day 7) (Figure 4.5).  CCR5 expression was higher in Tc1 than Tc2 cells on days 3 and 7 after 
transfer (Figure 4.5).  Tc2 cell expression of CCR5 was undetected on day 7 (Figure 4.5).  In 
the tumors, we found that CXCR3 was expressed similarly by Tc1 and Tc2 cells on day 3 but 
was higher for Tc1 cells on day 7 compared to Tc2 cells, where CXCR3 expression was 
undetected (Figure 4.5).  CCR4 gene expression was detected only at minimal levels in Tc1 
cells on day 7 (Figure 4.5).  CCR5 was also detectable only in Tc1 cells, but was found on 
days 3 and 7 (Figure 4.5).   
We then examined the chemokine receptor gene expression in host cells from TDLNs 
and tumors in Tc1 and Tc2 treated animals.  As we observed in donor cells, CXCR3 was 
more highly expressed than CCR4 or CCR5 in TDLNs and tumors of Tc1 and Tc2 treated 
animals (Figure 4.6).  In TDLNs, while on day 3 the CXCR3 expression was higher in Tc1 
treated animals, on day 7 it was higher in Tc2 treated animals (Figure 4.6).  CCR4, although 
only expressed at low or minimal levels in host cells of TDLNs, was also expressed higher in 
Tc1 treated animals on day 3 but higher in Tc2 treated animals on day 7 (Figure 4.6).  CCR5, 
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likewise, being expressed at low or minimal levels in host cells of TDLNs, was also 
expressed higher on day 3 in Tc1 treated animals and on day 7 in Tc2 treated animals (Figure 
4.6).  In the tumors of the Tc1 and Tc2 treated animals, CXCR3 was expressed higher by 
host cells than CCR4 or CCR5 Figure 4.6).  CXCR3 expression was higher in host cells of 
Tc1 treated animals on day 3 but was higher in host cells of Tc2 treated animals on day 7 
(Figure 4.6).  CCR4 expression was only detected in host cells of Tc2 treated animals on day 
7 after donor cell transfer (Figure 4.6).  CCR5 expression was found in host cells from Tc1 
and Tc2 treated mice on days 3 and 7 in the tumors (Figure 4.6).  The expression of CCR5 
was higher on the host cells from Tc2 vs. Tc1 treated animals on day 7 (Figure 4.6).  Overall, 
we found that CXCR3 is more highly expressed by donor and host cells compared to 
expression levels of CCR4 and CCR5 in TDLNs and tumors on days 3 and 7 after donor cell 
transfer.   
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Discussion 
 We have shown previously that cultured Tc1 and Tc2 cells are polarized into type I 
and type II populations, respectively, and that these populations of cells not only have 
different levels of PSGL-1 cell surface protein and gene expression of chemokine receptors 
but also appear to migrate to TDLNs and infiltrate tumors with different efficiencies (Figures 
2.6, 3.1, and 3.2).  Here we examined donor, host, and total tumor cells by real time RT-PCR 
for gene expression to evaluate genes which may contribute to the increased cell surface 
expression of PSGL-1 on Tc1 vs. Tc2 cells and to evaluate the role of chemokines in the 
recruitment of Tc1 vs. Tc2 cells to TDLNs and tumors.  We also evaluated cytokine gene 
expression to indicate whether the donor cells remained polarized after transfer.  We found 
that T-bet and the selectin ligand CD43 are expressed significantly higher in Tc1 than Tc2 
cells.  PSGL-1 and the selectin glycosylating enzymes we examined were not differentially 
expressed (mRNA) in Tc1 vs. Tc2 cells.  We also found that chemokine IP-10 was more 
highly expressed than either MIP-1a or MDC, particularly in tumors of Tc1 treated animals 
on day 7, and MDC gene expression was also higher in tumors of Tc1 treated animals on day 
7 compared to tumors of Tc2 treated animals. Overall, CXCR3 was expressed higher than 
either CCR4 or CCR5 by host and donor CD8+ cells in TDLNs and tumors of Tc1 and Tc2 
treated animals.  Finally, both host and donor CD8+ cells in Tc1 and Tc2 treated animals 
expressed higher levels of IFN−γ gene expression, overall, compared to IL-4. 
Although we previously found different levels of PSGL-1 selectin ligand on the cell 
surface of Tc1 and Tc2 cells by flow cytometry, we did not find differences in the mRNA 
levels of PSGL-1 or the glycosylating enzymes we examined (Figures 3.2 and 4.1).  
Therefore, it is possible that regulation of PSGL-1 expression in Tc1 vs. Tc2 cells is not 
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regulated at the transcription level.  Instead, mRNA of PSGL-1 and the enzymes we 
examined may be degraded more quickly in Tc2 cells or the glycosylating enzymes may not 
be as active in Tc2 cells compared to Tc1 cells.  Interestingly, we did find higher expression 
of T-bet and CD43 in Tc1 cells compared to Tc2 cells.  Even though PSGL-1 and CD43 are 
both P-selectin ligands, it appears that Tc1 and Tc2 cells express and possibly regulate the 
expression of these selectin ligands differently.  Our observation of T-bet expression being 
higher in Tc1 cells compared to Tc2 cells is an important finding.  Despite growing 
knowledge of type I and type II regulation in CD4+ T cells, including T-bet expression, very 
little is known about the transcriptional control of type I and type II phenotypes in CD8+ T 
cells.  T-bet is important for Th1 cell functions, and we suggest from our observations that T-
bet is also a key transcription factor for Tc1 cells (10-13).  It may be that T-bet is moderatlely 
expressed in Tc2 cells but is off-set by the expression of another, as yet unknown, 
transcription factor.  For example, T-bet type I activity is off-set by transcription factor 
GATA binding transcription factor-3 (GATA-3) type II activity in CD4+ T cells (10, 13).  
Thus, our data, together with studies on CD4+ T cell polarization, suggest that T-bet may be 
a key transcription factor for type-I signaling in both CD4+ and CD8+ T cells. 
  When we examined type I polarization of donor and host cells in the Tc1 and Tc2 
treated animals, we found that gene expression of IFN−γ was higher than IL-4, which was 
undetected in many samples.  This dominating IFN−γ expression indicates that the host cells 
in tumors of the Tc1 and Tc2 treated animals are type I cells, overall, and is supported by 
previous findings suggesting that type I host responses are required for both Tc1 and Tc2 
therapy (25-28).  We propose that IFN−γ expression may be another indicator of “tumor 
infiltrating phenotype” for CD8+ T cells, in addition to adhesion molecule expression (See 
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Chapter 3).  Importantly, IFN−γ gene expression by Tc2 cells in the tumors on day 7 after 
transfer is undetectable in addition to IL-4 expression and all three chemokine receptors we 
examined.  This suggests that Tc2 cells may be down-regulating gene expression after 
infiltrating into tumors.  It is unknown whether Tc1 cells are less susceptible to Treg activity 
in tumors, but we do know that giving recombinant IL-12, a type I cytokine used to polarize 
Tc1 cells in vitro, can reverse Treg activity in at least one tumor therapy study (29).  Treg 
cells are known to suppress anti-tumor activity and are a critical consideration for ACT 
therapy (30, 31).  Therefore, evaluating Treg activity in Tc1 vs. Tc2 treated animals, as well 
as the importance of type I cytokines, will be important components of our understanding of 
Tc1 and Tc2 therapy. 
 Another important consideration in evaluating the efficacy of Tc1 vs. Tc2 therapy is 
the role of type-specific or promiscuous chemokines in attracting both donor and host cells to 
reject the tumor (4, 14-20).  Notably, we found that the only type-specific chemokine we 
investigated that was upregulated in Tc1 vs. Tc2 treated animals was IP-10.  Type I 
chemokine IP-10 is induced through IFN-γ signaling and is expected to recruit predominantly 
type I T cells (4, 16, 18-20).  Because type I T cells are thought to be more effective in 
clearing tumor cells than type II T cells, several studies have examined the role of IP-10 in 
the recruitment of tumor infiltrating T cells (18-20).  Tumors cells transfected to express IP-
10 had increased infiltration by CD8+ T cells (19).  We found that IP-10 is highly expressed 
overall in the tumors of both Tc1 and Tc2 treated animals on days 3 and 7 after donor cell 
transfer.  Because we found that IP-10 is expressed significantly higher in tumors of Tc1 
treated animals on day 7, we suggest that Tc1 therapy may enhance the recruitment of type I 
CD8+ T cells to the tumor site through upregulation of IP-10.  However, we did not see an 
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increase in the number of total lymphocytes or CD8+ cells in tumors of Tc1 vs. Tc2 treated 
mice on days 3 and 7 (Figure 3.1).  We believe that an increase in the number of CD8+ cells 
recruited to tumors in Tc1 vs. Tc2 treated animals may occur after day 7, especially because 
IP-10 production in Tc1 treated animals has been shown to be bimodal in nature, declining 
after approximately 7 days following therapy and then peaking again at approximately 21 
days after therapy (20).  The observed high gene expression of IP-10 may not affect the 
number of CD8+ cells recruited to the tumors in Tc1 vs. Tc2 animals but may preferentially 
recruit type I CD8+ T cells to the tumors.  We need to evaluate IP-10 production and the 
recruitment of type I vs. type II CD8+ cells to the tumors in Tc1 and Tc2 treated animals to 
address these questions.  Expression of IP-10 receptor CXCR3 by tumor infiltrating donor 
and host cells suggests further that IP-10 may be critical for the tumor infiltration in the Tc1 
and Tc2 treated animals. 
 Our results further suggest that differential expression of chemokine receptors by 
donor and host cells may also play a role in ACT therapy.  When we examined CXCR3 
expression we found that it was expressed higher overall by donor and host CD8+ cells in 
TDLNs and tumors of Tc1 and Tc2 treated animals compared to CCR4 or CCR5 on days 3 
and 7 after donor cell transfer.  Type I specific receptor CCR5 expression by Tc1 cells was 
higher than Tc2 cells in TDLNs and tumors on both days 3 and 7, but type II specific 
receptor CCR4 expression was limited or undetected in both Tc1 and Tc2 cells.  These 
results together with the cytokine expression data suggest that the Tc1 donor cells maintain 
the Tc1 phenotype in vivo through day 7 after transfer but Tc2 cells may convert to a type I 
phenotype in vivo as early as day 3 after transfer.  A conversion of Tc2 to a type I phenotype 
in vivo may contribute to the delay or decreased efficacy of Tc2 vs. Tc1 therapy we and 
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others have observed.  Furthermore, Tc2 cells may need to alter their phenotype in vivo to 
express the “tumor infiltrating phenotype” we described previously as being expressed higher 
on Tc1 compared Tc2 cells.   
 Overall, these preliminary studies suggest roles for several molecules in the 
regulation of Tc1 and Tc2 phenotype, as well as the recruitment of CD8+ cells to tumors in 
Tc1 and Tc2 treated animals.  T-bet is a strong candidate for further investigation in the 
regulation of the Tc1 vs. Tc2 phenotype (See also Chapter 5) (10, 13).  PSGL-1 cell surface 
expression is higher in Tc1 than Tc2 cells, but it does not appear to be due to differential 
gene expression of either the PSGL-1 molecule itself of the glycosylating enzymes which 
post-translationally modify PSGL-1 for optimal selectin binding (9, 11, 12).  On the other 
hand, differential expression of the CD43 does appear to be due at least in part to differences 
in gene expression.  In addition, IFN−γ and its expression by donor cells, as expected from 
work by others, may be important for Tc1 and Tc2 therapy, as well as for promoting 
recruitment of cells to tumors (25-28).  IP-10 expression may be important for the 
recruitment of type I CD8+ cells in Tc1 vs. Tc2 treated animals, in conjunction with the 
expression of the CXCR3 chemokine receptor.  Future studies will need to confirm these real 
time RT-PCR observations and evaluate the requirement for these molecules, in order to 






























Figure 4.1:  Tc1 and Tc2 cell expression of genes important for selectin ligand synthesis.  
RNA was harvested from cultured Tc1 and Tc2 cells.  Expression of the following genes was 
evaluated using real time RT-PCR:  IFN-γ, IL-4, T-bet, PSGL-1, CD43, FucT-VII, B4GalT-I, 
ST3GalT-IV, ST3GalT-VI, and C2GlcNAcT-I.  All gene expression values are shown 





























Figure 4.2:  Chemokine expression in tumors of Tc1 and Tc2 treated animals.  Tumors 
from Tc1 and Tc2 treated animals were harvested 3 and 7 days after Tc1 and Tc2 treatment.  
RNA was harvested from the cells in the tumors and the expression of MIP-1α, MDC, and 
IP-10 was evaluated using real time RT-PCR.  All values are shown relative to the MDC 

































Figure 4.3: Cytokine expression by donor Tc1 and Tc2 cells in Tc1 and Tc2 treated 
animals.  Cells in TDLNs and tumors from Tc1 and Tc2 treated animals were harvested 3 
and 7 days after treatment.  Cells were sorted for GFP+CD8+ cells.  RNA was harvested from 
these cells and expression of IFN-γ and IL-4 was evaluated by real time RT-PCR.  All values 
are shown relative to the IFN-γ gene expression by Tc2 cells on day 3 (set to a value of 1.00).  
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Figure 4.4: Cytokine expression by host CD8+ cells in Tc1 and Tc2 treated animals.  
Cells in TDLNs and tumors from Tc1 and Tc2 treated animals were harvested 3 and 7 days 
after treatment.  Cells were sorted for GFP-CD8+ cells.  RNA was harvested from these cells 
and expression of IFN-γ and IL-4 was evaluated by real time RT-PCR.  All values are shown 
relative to the IFN-γ gene expression by host CD8+ cells in Tc2 treated animals on day 3 (set 










































Figure 4.5: Chemokine receptor expression by donor Tc1 and Tc2 cells in Tc1 and Tc2 
treated animals.  Cells in TDLNs and tumors from Tc1 and Tc2 treated animals were 
harvested 3 and 7 days after treatment.  Cells were sorted for GFP+CD8+ cells.  RNA was 
harvested from these cells and expression of CXCR3, CCR4, and CCR5 was evaluated by 
real time RT-PCR.  All values are shown relative to the CCR5 gene expression by Tc1 cells 
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Figure 4.6:  Chemokine receptor expression by host CD8+ cells in Tc1 and Tc2 treated 
animals.  Cells in TDLNs and tumors from Tc1 and Tc2 treated animals were harvested 3 
and 7 days after treatment.  Cells were sorted for GFP-CD8+ cells.  RNA was harvested from 
these cells and expression of CXCR3, CCR4, and CCR5 was evaluated by real time RT-
PCR.  All values are shown relative to the CCR5 gene expression by Tc1 cells on day 3 (set 
to a value of 1.00).  Tc1 vs. Tc2, p≤ .05* .p≤ .01**. 
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 ACT therapy has been used to treat animals and patients with tumors (1-4).  Tc1 cells 
have been shown to be more effective than Tc2 cells for therapy in several tumor models (5-
11).  Migration differences between Tc1 and Tc2 cells were previously proposed to 
contribute to this difference in therapeutic efficacy (6, 7, 10).  We developed a model to 
examine Tc1 vs. Tc2 trafficking in vivo (See Chapter 2) (12).  Previously in the lab, we 
transfected EL-4 thymoma tumor cells to express the p33 peptide antigen from lymphocytic 
choriomeningitis virus (p33.EL-4) (13).  In order to evaluate monoclonal CD8+ T cell 
responses specific for these tumors, we used P14 mice, which are transgenic for the TCR 
specific for p33 peptide in the context of MHC-I molecule H-2Db that is expressed by these 
p33.EL-4 tumors (14).  Other models have used intracellular labeling of amines or staining of 
cell surface proteins with antibodies to identify antigen-specific donor cells (6, 7, 10).  These 
methods have limitations, so we utilized green fluorescent protein (GFP) expression to track 
our donor cells (12, 15-17).    We crossed UBI.GFP mice that ubiquitously express GFP with 
the P14 mice, in order to generate a F1 generation of mice that express both GFP and the 
p33-specific TCR in the CD8+ T cell population (12).  We stimulated splenocytes from these 
mice with peptide under polarizing conditions to generate Tc1 and Tc2 cells for transfer (12).  
Donor cells were phenotyped before transfer using flow cytometry and real time RT-PCR.  
Tc1 or Tc2 donor cells were injected i.v. into tumor bearing mice. On days 3 and 7 after 
transfer, TDLNs and tumors were harvested.  The CD8+ T cells were examined for GFP and 
adhesion molecule expression by flow cytometry.   
We found significantly more Tc1 than Tc2 cells in TDLNs and tumors on days 3 and 
7 after transfer (Figure 3.1) (12).  Both Tc1 and Tc2 donor cells were found in TDLN and 
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tumor sites of p33 antigen-positive tumors and sites of p33 antigen-negative tumors (Figure 
3.5) (12).   More importantly, all CD8+ T cells isolated from the tumors on days 3 and 7 after 
therapy, regardless of host or donor origin and Tc1 or Tc2 phenotype, expressed high levels 
of adhesion molecules important for T cell migration (Figures 3.3, 3.4, and 3.7) (12). This 
was the case in p33 antigen-positive and antigen-negative tumors, which suggested that 
antigen does not alter the adhesion molecule expression of tumor infiltrating CD8+ T cells 
(Figures 3.6 and 3.7) (12). These cells expressed high levels of CD44, LFA-1, and PSGL-1, 
suggesting a “tumor infiltrating phenotype” that is required for tumor infiltration by CD8+ T 
cells (12).  Before transfer and 3 days after transfer, Tc1 cells expressed higher levels of the 
tumor infiltrating phenotype compared to Tc2 cells in vitro and in TDLNs (Figure 3.2) (12).  
Thus, increased Tc1 cell migration to TDLN and infiltration of tumors may be due to the 
higher expression of the tumor infiltrating phenotype compared to Tc2 cells.   
We then used real time RT-PCR to examine the gene expression of molecules which 
may contribute to the increased adhesion molecule expression on Tc1 cells we observed.  
Cultured Tc1 and Tc2 cells expressed similar levels of the PSGL-1 gene, as well as similar 
levels of genes for a variety of selectin glycosylating enzymes (Figure 4.1).  The gene 
expression of CD43, a ligand for P-selectin other than PSGL-1, was higher in Tc1 than Tc2 
cells (Figure 4.1).  More importantly, the gene expression of transcription factor T-bet was 
significantly higher in Tc1 than Tc2 cells (Figure 4.1).  Therefore, gene transcription of 
PSGL-1 and the glycosylating enzymes does not appear to contribute to the regulation of the 
surface expression of PSGL-1 by Tc1 and Tc2 cells.  Additionally, our findings suggest that 
T-bet is a strong candidate as a regulator of Tc1 vs. Tc2 phenotype. 
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When we used real time RT-PCR to examine the gene expression of cytokines, 
chemokines, and chemokine receptors by the cells in Tc1 or Tc2 treated animals, we found 
evidence of a predominant type-I response in both the Tc1 and Tc2 treated groups: IFN-γ, IP-
10, and CXCR3 expression.  Both donor and host CD8+ cells in tumors of Tc1 and Tc2 
treated animals expressed IFN-γ but not IL-4 (Figure 4.3 and 4.4).  Chemokine IP-10 was 
more highly expressed than either MIP-1α or MDC in the tumors of both Tc1 and Tc2 
treated animals (Figure 4.2).  Chemokine receptor CXCR3, which binds IP-10, was highly 
expressed by both donor and host CD8+ cells in the tumors (Figure 4.5 and 4.6).  Together 
these data suggest that IFN-γ, IP-10, and CXCR3 may be important molecules in anti-tumor 
responses, particularly for CD8+ T cell mediated responses. 
Therefore, our studies suggest that Tc1 and Tc2 therapies may be differentially 
effective due to differences in Tc1 and Tc2 donor cell migration and tumor infiltration in 
vivo.  These differences may result from differences in the cell surface expression of 
adhesion molecules.  Antigen does not appear to affect the phenotype of the donor cells after 
transfer, but does increase the number of infiltrating CD8+ cells.  Both Tc1 and Tc2 
treatment of tumor bearing animals results in type I responses, including the gene expression 
of IFN-γ, IP-10, and CXCR3, suggesting that differences in Tc1 vs. Tc2 therapy is not due to 
a qualtitative change in the phenotype of cells in the tumors, but perhaps due to differences in 
the quantitative expression of a type I phenotype in Tc1 vs. Tc2 treated animals.   
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Tumor infiltrating phenotype and Tc1 vs. Tc2 therapy 
 Tc1 therapy is more effective than Tc2 therapy in several tumor models (5-11).  We 
investigated whether differences in Tc1 and Tc2 cell migration and tumor infiltration may 
contribute to the difference in therapeutic efficacy based on evidence by previous studies that 
Tc1 and Tc2 cells may migrate differently (12).  We showed that in both Tc1 and Tc2 treated 
tumor bearing animals, the donor and host tumor infiltrating CD8+ T cells were all CD44 
high, LFA-1 high, and PSGL-1 high (Figures 3.4 and 3.7) (12).  This tumor infiltrating 
phenotype was more highly expressed by Tc1 and Tc2 cells in vitro and on day 3 in TDLNs 
after transfer (Figures 3.2 and 3.3) (12).  We also examined the expression of CD49d and 
α4β7 integrins but found little or no expression of these molecules by Tc1 and Tc2 cells in 
vitro (Figure 3.2) (12).  Since we concentrated our in vivo studies on those molecules that 
showed a significant difference in expression between Tc1 and Tc2 cells prior to transfer, we 
do not have conclusive data that the expression of these integrin molecules does not change 
after transfer, particularly for Tc1 cells, which may contribute to the differences in initial 
migration by Tc1 and Tc2 cells.  (This initial migration may be affected by Tc1 or Tc2 cells 
being held within the lung instead of continuing into circulation.)  However, since Tc1 cells 
migrate and infiltrate tumor more effectively than Tc2 cells, we believe that the difference in 
Tc1 and Tc2 cell phenotype before transfer contributes to these differences in migration and 
tumor infiltration.   Migration to TDLNs and tumor infiltration by transferred cells has been 
shown to be important for ACT therapy (1, 18-20).  Taken together this suggests that the 
increased migration and tumor infiltration by Tc1 vs. Tc2 cells in vivo contributes to the 
increased efficacy of Tc1 vs. Tc2 cell therapy. 
 130 
How the trafficking of Tc1 vs. Tc2 cells may affect therapy is not yet clear.  However 
we do know that host responses are important for both therapies, so the increased number of 
Tc1 vs. Tc2 cells at TDLNs and tumors may affect host cell responses differently (21-23).  
One proposed theory is that Tc1 donor cells promote the recruitment of more type I host 
CD8+ T cells to the tumor sites compared to Tc2 donor cells (23).  We found that the number 
of tumor infiltrating total lymphocytes and CD8+ T cells was the same in both Tc1 and Tc2 
treated animals, so Tc1 and Tc2 therapy do not promote different numbers of host cells in our 
model (Figure 3.1) (12).  We do use only 1x106 donor cells, which is sufficient to observe 
differences in Tc1 vs. Tc2 therapy and trafficking in vivo, but this therapeutic dose may not 
be sufficient to significantly impact the number of tumor infiltrating host CD8+ T cells that 
has been reported by others (23).   
Type I effector T cell responses, particularly because of interferon (IFN)−γ 
production, and tumor infiltration by T cells have been shown to be important for tumor 
clearance (3, 21-32).  Tc1 cells do produce more IFN-γ than Tc2 cells, and our preliminary 
studies suggest that CD8+ cells in tumors of both Tc1 and Tc2 treated mice produce IFN−γ, 
but no IL-4 (Figure 4.3).  This suggests that while Tc1 and Tc2 donor cells express different 
type I vs. type II cytokine genes before transfer, tumor infiltrating CD8+ cells express only 
type I cytokine gene production (Figure 4.1 and 4.3).  A possible role for IFN−γ in T cell 
tumor infiltration is that IFN−γ promotes the production of chemokine IP-10.  Expression of 
IP-10 by tumor cells has beeen shown to increase tumor infiltration by CD8+ T cells (31).  
Because IP-10 binds to receptor CXCR3, which is expressed by Tc1 and Tc2 cells before and 
after transfer, IP-10 may be the key chemokine for recruiting donor cells to the tumor site.  
More Tc1 cells may infiltrate tumors in response to IP-10 because IP-10 may promote the 
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recruitment of Type-I cells (31).  We did find increased production of IP-10 in the tumors of 
Tc1 treated animals on day 7 compared to Tc2 treated animals, which supports the proposal 
that higher IFN-γ production by Tc1 cells in the tumors may promote increased chemokine 
production, which may in turn preferentially recruit type-I cells (Figure 4.2).  Even though 
we did find a difference in donor cell tumor infiltration, we did not find a difference in the 
number of tumor infiltrating host CD8+ T cells in Tc1 and Tc2 therapy (Figure 3.1).  
However, it is important to note that we did not evaluate activity of the infiltrating host cells 
other than cytokine and chemokine receptor gene expression that suggested type-I host 
responses in both Tc1 and Tc2 treated animals (Figures 4.4 and 4.6).  Other functions of host 
CD8+ T cells, such as cytolytic activity, may be impacted significantly by the cytokine 
production of Tc1 vs. Tc2 cells, altering the efficacy of Tc1 and Tc2 therapies.   
Type I and type II cytokines have been shown to have different effects on responding 
anti-tumor effector CD8+ T cells (3, 30).  Type I cytokines IFN−γ and interleukin (IL)-12 
have been shown to promote tumor rejection by CD8+ T cells, while type II cytokine IL-10 
has been shown to suppress the activity of CD8+ T cells responding to tumors (3, 30).  
Therefore, because IFN−γ along with IL-12 are produced by Tc1 cells and IL-10 is produced 
by Tc2 cells, the transferred donor cells may promote anti-tumor responses or suppress anti-
tumor responses by host cells, respectively.  While we and others have found that both Tc1 
and Tc2 cells produce IFN−γ, it is likely that the low level of IFN−γ production by Tc2 cells 
is not sufficient to promote the same effects as the high level of IFN−γ produced by Tc1 cells 
(45).   
IFN−γ promotes several aspects of CD8+ T cell activity (33).  IFN−γ signals through 
signal transactivator of T cells (STAT)-1 and promotes IL-12 production, which in turn 
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promotes further IFN−γ production through STAT-4 signaling (33).  Together, IFN−γ and 
IL-12 can promote expression of adhesion molecules by T cells (34).  Therefore, the IFN−γ 
production in animals with Tc1 or Tc2 therapy may promote the upregulation of adhesion 
molecules on host and donor CD8+ T cells to the tumor infiltrating phenotype.  This type I 
STAT signaling could contribute to the observed change in Tc2 adhesion molecule 
expression from in vitro to in vivo phenotype.  In vitro and on day 3 in TDLNs after transfer, 
Tc2 cells expressed adhesion molecules but not at high levels (12).  On day 7 in TDLNs after 
transfer, Tc2 cells expressed high levels of adhesion molecules (12).  Since Tc2 cells produce 
low levels of IFN−γ, it is likely that IFN−γ production by host cells rather than donor Tc2 
cells leads to the enhanced adhesion molecule expression on donor Tc2 cells.   
The cytolytic activity of CD8+ T cells is also affected by IFN−γ and IL-12 signaling 
(33).   During T cell priming, APCs provide the necessary primary (MHC:peptide complex) 
and secondary (co-stimulatory molecules) signaling needed for T cell activation, but recently 
it has been reported that a third signal is needed for optimal effector cell activity, which may 
explain previous reports of incomplete priming or non-responsiveness of T cells in animals 
injected with tumor cells (34-44).  Both IFN−γ and IL-12 can provide this important third 
signal in vitro and in vivo (37-40, 42, 44).  Therefore, while donor cells are activated before 
transfer, the cytokine production by Tc1 cells may contribute to the needed third signal for 
both host and donor cell activity, leading to increased tumor clearance early after Tc1 cell 
therapy.  Host CD8+ T cells may also contribute IFN−γ and IL-12 to the third signal for 
effector cell activity.  In contrast, Tc2 production of IL-10 may suppress this signaling, 
thereby suppressing the activity of host CD8+ T cells within tumors, leading to diminished 
efficacy in Tc2 vs. Tc1 therapy.  This IL-10 production by Tc2 cells may work in synergy 
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with IL-10 production by regulatory T (Treg) cells to suppress host anti-tumor activity in situ 
rather than tumor infiltration (3, 30).  Additionally, it is not known whether Tregs affect Tc1 
vs. Tc2 cell activity equally.  Because Tregs are known to accumulate in tumors, the 
sensitivity and response of donor Tc1 vs. Tc2 cells to Treg activity may be an important 
factor determining the efficacy of Tc1 vs. Tc2 therapy (3, 30). 
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Why more Tc1 than Tc2 cells in TDLNs and tumors? 
 Our study, along with data from other studies, clearly demonstrates that more Tc1 
than Tc2 cells are found in TDLNs and tumors.  There are several possible explanations as to 
why more Tc1 than Tc2 cells are found at these sites: 1) Tc1 cells undergo expansion and/or 
Tc2 cells undergo contraction after transfer; 2) More cells in Tc1 cultures express the 
appropriate activation/adhesion phenotype for trafficking in vivo than cells in Tc2 cultures; 
and 3) Tc2 cells express a phenotype sufficient for migration and tumor infiltration but 
exhibit less than optimal adhesion molecule function in vivo.   We address these explanations 
and what role antigen may play in CD8+ T cell tumor infiltration in the following discussion. 
 
Proliferation, Apoptosis, and Activation (or Memory) Phenotype 
During T cell responses, there is an expansion phase dominated by proliferation and a 
contraction phase dominated by apoptosis regulating the number of responding T cells 
(increasing and decreasing cell numbers, respectively).  Donor cells have proliferation 
potential at the time that they are transferred into the tumor-bearing recipient mice, and since 
the donor cells can come in contact with antigen after transfer in vivo, it is expected that the 
donor cells would proliferate.  As anticipated, studies have shown evidence suggesting that 
both tumor-specific Tc1 and Tc2 cells proliferate after transfer into tumor-bearing mice (13, 
23).  It is therefore unlikely that differences in expansion of Tc1 vs. Tc2 cells can explain our 
differences in the number of donor cells in TDLNs and tumors, since we and others have 
evidence demonstrating that Tc1 and Tc2 cell populations proliferate with similar 
efficiencies in vitro and ex vivo (Flood PM, unpublished observations, 45).  Therefore, 
differences in proliferation rates are not likely to contribute to the difference in the number of 
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Tc1 vs. Tc2 cells in TDLNs and tumors after donor cell transfer.  However, studies have not 
reported on Tc1 vs. Tc2 cell apoptosis.  It is possible that the Tc2 cells undergo a contraction 
phase earlier after transfer than the Tc1 cells.   
Signals that promote T cell survival can also contribute to the development of 
memory cell subsets (46-48).  We have evidence to suggest that Tc1 and Tc2 cell cultures 
have different activation phenotypes, potentially reflecting the development of different 
memory cell populations (12).  Following activation, T cells upregulate CD44 and 
downregulate CD62L (46-48).  However, as cells develop into memory cell subsets, these 
cells remain CD44+ but can be distinguished by CD62L expression (46-48).  Effector 
memory (TEM) cells are CD62L- and central memory (TCM) cells are CD62L+ (46-48).  
Presumably, this applies to “classical” CD8+ T cells.  Whether this applies similarly to 
polarized CD8+ T cells is not clear.  We found that Tc1 cell cultures are CD44+ and are 
CD62L+/high  (Figure 3.2) (12).  Tc2 cell cultures are predominantly CD44+ but CD62L- 
(Figure 3.2) (12).  Therefore, Tc1 cultures may contain more cells with the TCM phenotype, 
and Tc2 cultures may have more cells with the TEM phenotype. Studies have shown that 
CD44+ T cells and CD62L+ T cells are more effective in adoptive cell transfer therapy (1, 19, 
20).  Therefore, this CD44 and CD62L phenotype of Tc1 vs. Tc2 cultures likely contributes 
to differences in Tc1 vs. Tc2 therapy.  Importantly, since both CD44 and CD62L are 
adhesion molecules, this further suggests that trafficking of cells may contribute to whether T 
cells are effective for tumor therapy and differences in Tc1 vs. Tc2 therapy may be due in 
part to the difference in phenotype. 
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Regulation of adhesion molecule expression by Tc1 and Tc2 cells 
 Adhesion molecules including integrins, selectins, and their ligands regulate T cell 
trafficking (17, 34, 47, 49-53).  As stated above, we examined the expression of adhesion 
molecules by Tc1 and Tc2 cells in vitro before transfer and also after transfer.  In addition to 
CD62L and CD44 expression, we also determined the expression of LFA-1 and PSGL-1.  
Tumor infiltrating CD8+ T cells all expressed high levels of CD44, LFA-1, and PSGL-1 
(Figure 3.4 and 3.7) (12).  It is not clear whether each of these molecules is individually 
important for tumor infiltration or whether ligand binding for one adhesion molecule 
promotes the expression of the other adhesion molecules.  Although we now know that Tc1 
cells express higher levels of LFA-1, CD44, CD62L, and PSGL-1 compared to Tc2 cells in 
vitro, we have not determined why Tc1 cells express higher levels of these molecules (Figure 
3.2).  Expression of adhesion molecules can be regulated at several levels, including gene 
transcription and signaling or post-translational modification (34, 51, 54).  Below we discuss 
examples transcription factors and signaling that can promote the upregulation of adhesion 
molecules and examples only of modifications made to PSGL-1 and CD44.   
 
Gene Transcription and Signaling 
Key molecules and transcription factors which regulate the expression of adhesion 
molecules have been identified, however we have limited knowledge of type I vs. type II 
response regulation of these molecules (33).  This limited knowledge is further complicated 
by the current lack of understanding of type I vs. type II signaling in CD8+ T cells, because 
most studies examining signaling and gene expression in T cells have focused on the CD4+ 
populations.  Methods to generate Tc1 and Tc2 cells in vitro provide some insight into what 
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transcription factors and signaling pathways are important for type I and type II polarization 
in CD8+ T cells.  In a study examining calcium vs. protein kinase C (PKC) signaling to 
polarize CD8+ T cells, Noble and Kemeny found that Tc1 and Tc2 cells are generated by 
increased calcium and PKC signaling following TCR engagement, respectively (55).    
Additionally, when generating Tc1 and Tc2 cells in vitro, recombinant type-specific 
cytokines and antibodies against type-specific cytokines are used (5-13, 21-24, 56).  Type I 
polarization includes adding rIL-12 and blocking IL-4, while type II polarization includes 
adding IL-4 and blocking IL-12 and IFN−γ (5-13, 21-24, 56).  Cytokine signaling through 
cytokine receptors leads to STAT signaling (33, 57).  Type I signaling goes through STAT1 
and STAT4, but type II signaling goes through STAT6 (33, 57).  Downstream of STAT1 and 
STAT4 is T-bet (33, 57).  T-bet is perhaps the key transcription factor regulating type I CD4+ 
T (Th1) cell activity (57).  T-bet has also been identified in CD8+ T cells and shown to 
regulate genes involved in cytolytic activity (33).  In type II CD4+ (Th2) cells, GATA-
binding transcription factor 3 (GATA-3) is a key transcription factor (57).  Unlike T-bet, 
GATA-3 is not expressed in CD8+ T cells and actually promotes the development of CD4+ T 
cells (58).  Thus, T-bet is of particular interest as a candidate for differences in Tc1 vs. Tc2 
signaling and cellular activity.   
T-bet is possibly the key transcription factor responsible for the increased level of 
adhesion molecule expression on Tc1 vs. Tc2 cells.  T-bet has been shown to be critical for 
migration and expression of enzymes important for adhesion molecule expression by Th1 
cells (34, 59-61).  IL-12 and IFN−γ expressed by type I cells bind their respective receptors 
and signal through STAT-4 and STAT-1, respectively (33, 57).  This promotes T-bet activity, 
which in turn promotes IFN−γ and IL-12 productions (33, 57).  This cyclic signaling is 
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believed to occur in CD8+ T cells as well (33).  Therefore, by adding IL-12 in Tc1 cultures 
and blocking IL-12 and IFN−γ in Tc2 cultures, T-bet signaling is likely promoted in Tc1 and 
blocked in Tc2 cells.  Our preliminary studies do suggest that Tc1 cells express higher levels 
of T-bet gene expression (Figure 4.1).  Furthermore, if T-bet is indeed upregulated in Tc1 
cells, then adhesion molecule expression regulated by Tc1 cells may be upregulated through 
T-bet.   
 
Post-Translational Modification 
Adhesion molecule expression is not only regulated at the transcriptional level but 
also at post-translational modification (34, 51, 54, 62).  For example, both CD44 and PSGL-1 
undergo post-translational modification (34, 51, 54, 62).  In order for PSGL-1 to be active, it 
must be glycosylated at numerous sites (34).  Several enzymes are known to be important for 
PSGL-1 expression in type I T cells, including core 2 β1,6 N-acetylglucosaminyl- 
transferase I, fucosyltransferase VII, and α 2,3-sialyltransferase IV (34, 62, 63).  Considering 
the possible role for T-bet signaling in Tc1 cell function, it is interesting that T-bet knockout 
studies have shown that these enzymes are regulated by T-bet (59, 60).  Consequently, our 
observation of higher expression of PSGL-1 on Tc1 cells in vitro and on day 3 after transfer, 
could be due to upregulation of T-bet as well as the enzymes responsible for PSGL-1 
expression in Tc1 cells compared to Tc2 cells.  Although our preliminary studies do suggest 
a higher level of T-bet gene expression in Tc1 vs. Tc2 cells, the gene expression of these 
enzymes does not appear to be different between Tc1 and Tc2 cells (Figure 4.1). Therefore, 
through T-bet signaling, Tc1 cells may upregulate translatation or activity of these enzymes 
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more than Tc2 cells, leading to higher expression of PSGL-1.  The role T-bet plays in the 
post-translational modification of CD62L, CD44, and LFA-1 is not known. 
 CD44 molecules are class I transmembrane glycoproteins encoded by one gene (54).  
The isoforms are generated through alternative splicing and post-translational modifications 
(54, 64).  As could be expected due to the variety of CD44 isoforms, CD44 has a variety of 
functions (54, 64, 65).  CD44 expression is also regulated at the cell surface, through 
proteolytic cleavage (54, 64).  The enzyme mediating the cleavage has not yet been identified 
(54).  CD44 is upregulated after T cell activation and is also expressed on memory cells (46-
48).  We found that both Tc1 and Tc2 donor cells express CD44 in vitro after stimulation and 
also at TDLNs and tumors after transfer into tumor-bearing mice (Figures 3.2-3.4) (12).  Tc1 
cells expressed higher levels of CD44 in vitro and 3 days after transfer in the TDLNs 
(Figures 3.2 and 3.3) (12).  Because of the multidisciplinary functions and isoforms of CD44, 
it is difficult to determine the impact of higher CD44 expression on Tc1 vs. Tc2 cells.  We 
believe that higher CD44 expression does play a role in increased migration and tumor 
infiltration by Tc1 vs. Tc2 cells in vivo. Importantly, we do not know whether Tc1 and Tc2 
cells express similar levels of the various CD44 isoforms, only that CD44 expression overall 
is higher in Tc1 cells in vitro and in TDLNs on day 3 after transfer.   
 
Adhesion molecule function in Tc1 and Tc2 cells 
 We have limited knowledge concerning the regulation of adhesion molecule function 
in CD8+ T cells (17, 34, 47, 49-53).  There is some evidence of how adhesion molecules 
function in CD4+ T cells, although not necessarily in polarized Th1 or Th2 cells (17, 34, 47, 
49-53).  Additionally, most studies have focused on the change in adhesion molecule 
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function in naïve vs. activated T cells, not subsequent regulation of function after T cells 
have been activated.  In general, upon activation, T cell adhesion molecules convert to the 
active conformation, redistribute on the cell surface, and associate with intracellular signaling 
molecules (49-52, 54).  While we have shown that Tc1 and Tc2 cells express different levels 
of adhesion molecules CD62L, CD44, LFA-1, and PSGL-1 in vitro but similar levels of 
adhesion molecules within tumors, we do not know whether these adhesion molecules 
function equally in both Tc1 and Tc2 cells (Figures 3.2-3.4) (12).  Therefore, in addition to 
the difference in expression, Tc1 and Tc2 cells may migrate differently due to differences in 
adhesion molecule functions.  Since expressed adhesion molecules function not only to 
mediate adhesion but also to convey signaling, the function of adhesion molecules is not 
purely based on the expression level of the adhesion molecule, but also on several other 
factors (34, 47, 49-53, 66).  Many adhesion molecules have inactive and active 
conformations, as well as the distribution of the adhesion molecule in active conformation, 
particularly within the immunological synapse, is critical for adhesion and signaling (66-69).  
At each of these levels, the function of adhesion molecules can be controlled.  Below, we’ve 
focused on the functions of LFA-1. 
   
Adhesion 
 Most adhesion molecules are known for their adhesive properties.  Integrins, 
including LFA-1 have active and inactive conformations, which result in the alteration of the 
affinity of the LFA-1 αL and β2 subunits (49-51, 66- 68).  LFA-1 changes from inactive to 
active conformation as a result of chemokines binding to their receptors (66).  This inside-out 
signaling stimulated by the binding of chemokines involves the small GTPase RAP1, 
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phosphatidylinositol 3-kinase (PI3K), and mitogen-activated protein kinase pathways (66).  
LFA-1 is believed to have three affinity states termed low, intermediate, and high affinities 
(68).  It has been proposed that each of these affinity states may have different functions (68).  
The low affinity state may mediate loose or rolling adhesion, permitting transient interaction 
between LFA-1 and its ligands, such as ICAM-I (68).  Intermediate affinity is proposed more 
variety in interactions between LFA-1 and its ligands (68).  Importantly, the high affinity 
state is proposed to be the optimal state for LFA-1 mediated signaling, which is described 
below (68).   
Studies have shown that Th1 and Th2 cells respond differently to chemokines, which 
is not surprising because the cells express different chemokine receptors (70, 71).  However, 
what is surprising is that Th1 cells have been shown to migrate across endothelial cells 
independently of chemokines (72).  This chemokine-independent transmigration was blocked 
by antibodies against either CD44 or LFA-1 and was blocked by inhibitors of PI3K, 
suggesting that although LFA-1 affinity is enhanced after chemokine binding, the affinity of 
LFA-1 may be sufficient for function without increasing the affinity through chemokine 
signaling (72).  Notably, this did not occur in Th2 cells, suggesting that Th1 cells require 
different signals for migration than Th2 cells (72).  Perhaps Tc1 and Tc2 cells also differ in 
chemokine-independent regulation of transendothelial migration through LFA-1 and CD44.  
It is possible that Tc1 and Tc2 cells may express LFA-1 at similar levels (valency) but not 
necessarily in the same affinity state or even require the same chemokine signaling to change 
the affinity of LFA-1.  We have shown evidence that more cells in Tc1 cultures express high 
levels of LFA-1 than cells in Tc2 cultures, but we do not know whether Tc1 and Tc2 cells 
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with high LFA-1 expression have similar LFA-1 affinity states or respond similarly to 
signaling dependent or independent of chemokines (Figure 3.2) (12). 
 
Signaling 
 Many adhesion molecules also have signaling functions and may act as co-receptors 
for signaling molecules.  Clustering of molecules is important for signaling transduction.  
Both LFA-1 and CD44 undergo clustering (54, 68).  As mentioned above, it is proposed that 
the high affinity of LFA-1 is the conformation that mediates signaling (68).  Lateral mobility 
of LFA-1 in lipid rafts permits the clustering of LFA-1 molecules (68, 73).  Clustering of 
LFA-1 has been examined primarily during the priming of naïve T cells.  During T cell 
activation, LFA-1 localizes within the central supramolecular activation complex (SMAC) 
and then moves to the peripheral SMAC, where Talin is localized (66, 68).  When LFA-1 is 
clustered and binding to intercellular adhesion molecule-1 (ICAM-I), it is proposed that Talin 
anchors the clusters to the cytoskeleton but molecules can still interact with LFA-1 to 
transduce signaling (66, 68, 73).  LFA-1 binding to ICAM-I results in calcium signaling and 
promotes further signaling and transcription activation (66, 68).  The dynamic function of 
LFA-1 to mediate adhesion and signaling, particularly in the SMAC, and the different 
affinities of LFA-1 conformation states demonstrates the complexity of adhesion molecules 
function and regulation in T cells.   Again, while we demonstrated that Tc1 cells express 
higher LFA-1 in vitro compared to Tc2 cells, we don’t know whether the localization of 
LFA-1 in lipid rafts or mobility in and out of SMACs is different between Tc1 and Tc2 cells 
(Figure 3.2) (12). 
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What is the role of antigen in Tc1 and Tc2 cell trafficking? 
 Antigen presentation to T cells not only activates and restimulates the T cells, which 
leads to changes in gene expression and phenotype, but also regulates T cell function (45, 
74).  Specifically, target cell antigen recognition by antigen-specific T cells promotes target 
cell killing and antigen recognition of antigen expression on endothelial cells promotes 
transendothelial migration (74).  In vitro studies have shown that antigen expression by 
endothelial cells affects whether T cells initially kill the endothelium, arrest along the 
endothelium during migration, or continue to proceed in transendothelial migration into 
inflamed tissue (74).  Tumor infiltration by CD8+ T cells has been shown to be enhanced by 
antigen expression by tumor cells (75-78).  Previously, it was unclear whether Tc1 or Tc2 
cells migrated or infiltrated tumors differently, including whether they respond differently to 
antigen expression by tumors.   
In order to examine the role of antigen expression by tumors in Tc1 vs. Tc2 
trafficking in vivo, we injected mice with p33-expressing EL-4 tumor (p33.EL-4) cells in the 
right flank and parental (p33 negative) EL-4 tumor cells in the left flank.  Tc1 and Tc2 cells 
generated from GFPxP14 splenocytes were then transferred i.v. into the tumor-bearing mice 
5-7 days later.  We then compared the number and phenotype of donor Tc1 and Tc2 cells in 
TDLNs and tumors 3 and 7 days after transfer.  We found donor cells in both EL-4 and 
p33.EL-4 TDLNs and tumors on both days (Figure 3.5) (12).  Tc1 cell numbers were higher 
compared to Tc2 cell numbers at the same site (Figure 3.5) (12).  Again, we conclude that 
Tc1 cells have more efficient trafficking than Tc2 cells.  Interestingly, we found that the 
number of both Tc1 and Tc2 cells was higher in the p33.EL-4 vs. EL-4 TDLNs and tumors, 
suggesting that while the expression of antigen does not appear to determine the differences 
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in Tc1 vs. Tc2 cell migration, it does play a role in the migration and tumor infiltration of 
antigen-specific Tc1 and Tc2 cells (Figure 3.5) (12).  Expression of antigen may promote the 
expansion of donor cells, inhibit the contraction of donor cells, or mediate the migration and 
tumor infiltration process, thus leading to the observed increase in Tc1 and Tc2 donor cells in 
TDLNs and tumor sites of p33.EL-4 tumors.  It is also important to note that host CD8+ T 
cell expression of Vβ8 TCR, which is the TCR expressed by donor cells specific for p33 
antigen, was higher in the host CD8+ T cells isolated from p33.EL-4 tumors, also supporting 
a role for antigen expression in the recruitment of endogenous CD8+ T cells (data not shown) 
(12).  Whether endothelial cells sufficiently present antigen to stimulate proliferation is still 
in question.  Although antigen exposure can promote changes in T cell phenotype, we found 
no significant differences in the phenotypes of donor cells in the p33 antigen-positive vs. 
antigen-negative sites (Figure 3.6) (12).  It is not clear whether antigen expression by tumors 
affected the Tc1 and Tc2 cells similarly other than the increased number of cells in the 
TDLNs and tumors. 
 
Antigen expression by endothelial cells and transendothelial migration 
 As stated above, the expression of antigen by endothelial cells impacts T cell 
interaction with the endothelial cells (74).  Using several antigen-specific T cell models, 
CD4+ and CD8+ T cells have been shown to transmigrate across activated endothelium 
presenting cognate antigen more efficiently than activated endothelium not expressing 
cognate antigen (79-81).  Antigen-specific CD4+ T cells migrated across IFN−γ activated 
endothelial cell layers in vitro and did not proliferate, and those T cells that proliferated in 
response to antigen expression on endothelial cells did not migrate (79).  Two studies 
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examining the response of antigen-specific CD8+ T cells have suggested that antigen 
expression by endothelial cells may regulate the responsiveness of CD8+ T cells (80-81).  
Effector CD8+ T cells killed cytokine-activated peptide pulsed endothelial cells but did not 
kill resting peptide pulsed endothelial cells (80).  Also, CD8+ T cells rested for two weeks 
after restimulation were examined for migration properties (80).  These CD8+ T cells 
migrated readily across cytokine-activated endothelial cell layers but not across resting 
endothelial cells, resting peptide-pulsed endothelial cells, or even activated peptide-pulsed 
endothelial cells (80).  This suggested that antigen presentation by endothelial cells may 
inhibit T cell migration, but this study was limited to only those CD8+ T cells which had been 
resting and likely progressed into memory cells, not effector cells.  Additionally, while this 
study was conducted in vitro, another study conducted by the same group to examine the role 
of antigen in T cell transendothelial migration in vivo, they found that antigen presentation by 
endothelial cells promoted CD8+ T cell diapedesis (81).  Whether antigen definitively 
promotes transendothelial migration by activated CD8+ T cell is still being investigated.  Our 
study and others demonstrate that antigen does affect tumor infiltration, although the exact 
mechanism is unknown (Figure 3.5) (12, 75-78).  It is certainly unknown whether polarized 
Tc1 and Tc2 cells migrate differently across endothelium presenting antigen. 
 
Antigen expression and tumor infiltration 
 Previous studies have shown that antigen expression by tumors can regulate the 
infiltration and distribution of antigen-specific T cells in a tumor (75-78).  An early study by 
Boissonas et al. that examined the role of antigen in CD8+ tumor responses found that 
activated antigen-specific CD8+ T cells when transferred into mice bearing antigen-negative 
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tumors still infiltrated into the tumors despite the lack of cognate antigen expression (75).  
Another study using a different model showed that indeed activated T cells, both CD4+ and 
CD8+ cells, are able to infiltrate cognate antigen-negative tumors, provided that the cells are 
primed elsewhere, i.e. in vitro or at another site in vivo (76).   
More recent studies have examined the actual movement of adoptively transferred 
CD8+ T cells within antigen-positive and antigen-negative tumors using two-photon 
microscopy (77, 78).  Antigen presentation by tumors was shown to promote continued 
migration of antigen-specific CD8+ T cells (77).  Boissonas et al conducted a similar study 
where antigen-specific CD8+ T cells were shown to arrest when in contact with antigen-
positive cells, presumably to mediate cell killing, and then migration was restored and upon 
contact with another tumor cell, the CD8+ T cells arrested, again (78).  As a result, Boissonas 
et al. proposed a model for the role of antigen in the CD8+ T cell tumor infiltration and tumor 
cell killing where the cycle of migration, arrest, and killing continues until the T cells are 
exhausted or suppressed (78).  The movement of the antigen-specific CD8+ T cells in this 
study was very interesting.  Early after transfer, the donor cells in the antigen-positive tumor 
had very specific-somewhat limited movement, while the donor cells in antigen-negative 
tumors had more random movement (78).  Later after transfer and after significant tumor cell 
killing, the donor cells in the antigen-positive tumors had increased movement, comparable 
to the movement of the donor cells in antigen-negative tumors (78).  Importantly, this study 
and others have documented increased tumor infiltration by donor cells in antigen-positive 
vs. antigen-negative tumors (75-78).  
We found the same results in our study: donor Tc1 and Tc2 cells infiltrate the 
antigen-positive tumors in higher numbers compared to the antigen-negative tumors (Figure 
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3.5) (12).  The before-mentioned study also found that the donor cells appear to infiltrate 
tumors form the peripheral edges and then infiltrate further into the center of the tumor (78).  
Donor cells infiltrated only the peripheral edges of the antigen-negative tumors, but 
infiltrated further into the center of the antigen-positive tumor (78).  It would be interesting to 
determine whether Tc1 and Tc2 cells penetrate into the center of the antigen-positive tumors 
in a similar pattern.  Because we considered tumor infiltrating cells to include those cells 
which we could collect by simply harvesting the tumor, it is possible that many of the donor 
cells we identified were located within the tumor vasculature.  More Tc2 cells may arrest in 
the tumor vasculature compared to Tc1 cells, since we know that the mechanisms of 
transendothelial migration for Th1 and Th2 cells appear to differ and Tc1 cells appear to 
have higher migration efficiency overall in vivo.  Also, it would be interesting to find 




How does this apply to ACT therapy? 
Our study suggests that indeed differences between Tc1 and Tc2 therapies may be 
due to the difference in migration properties of Tc1 and Tc2 cells, including their adhesion 
molecule expression (Figures 3.1-3.4) (12).  Because CD8+ T cells are being used for tumor 
therapy in patients, Tc1 and Tc2 tumor therapy models offer a unique approach for 
understanding CD8+ T cell migration and tumor infiltration in vivo, particularly how CD8+ T 
cell trafficking affects the efficacy of ACT therapy (1-12, 21-24).  For example, all the tumor 
infiltrating CD8+ T cells express a tumor infiltrating phenotype: CD44 high, LFA-1 high, and 
PSGL-1 high (Figures 3.4 and 3.7) (12).  Expression of CD44, LFA-1, and PSGL-1 may be 
important for tumor infiltration by mediating loose and tight adhesion followed by 
transendothelial migration into the tumors.  Several studies have suggested that these 
adhesion molecules work together to mediate adhesion (82-84).  For example, crosslinking of 
PSGL-1 has been shown to stimulate clustering of LFA-1 and subsequent binding to ICAM-1 
in Th1 cells in vitro (84).  We do not yet know whether these adhesion molecules work in 
concert, in sequence, or individually.  We did find that both donor and host CD8+ T cells in 
the tumor express the tumor infiltrating phenotype, this suggests that cells cultured in vitro 
for tumor therapy need to express this tumor infiltrating phenotype, either before transfer or 
by acquiring the phenotype in vivo, in order to effectively migrate to and infiltrate the tumor 
(Figures 3.4 and 3.7) (12).     
 We propose that adhesion molecule expression and antigen specificity of T cells used 
in ACT therapy is an important consideration when preparing the cells for transfer.  Our 
study and those by others have clearly demonstrated that donor cell expression of CD62L, 
CD44, LFA-1, and PSGL-1 is important for promoting migration of donor cells and tumor 
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rejection (Figures 3.2-3.4) (1, 2, 12, 18- 20, 85-89).  Transferred cells must have the 
appropriate phenotype and state of activation, neither naïve nor late effector cells (1-4, 30).  
The donor cells should also be specific for tumor antigens that are expressed by tumor cells 
(1-4, 30).  Development of antigen loss variants will complicate the antigen-specific response 
by transferred donor cells (1-4, 30).  However, we have corroborating evidence that activated 
T cells will infiltrate tumor not expressing the cognate antigen (12, 75-78).  The lack of 
antigen expression may limit the efficacy of therapy by permitting premature exhaustion or 
contraction of the donor cell populations (1, 2).    
 While ACT therapy certainly is feasible in patients, it is important to remember that 
treatment protocols for individual patients will need to be tailored to their needs (4, 90).  The 
current paradigm for treatment considered by tumor immunologists is that immunotherapies, 
including ACT therapy, will probably have to be combined with more traditional treatments 
and other immunotherapies (4, 90).  For example, patients will likely still require surgery, 
when possible, to remove as much of a tumor as possible, followed by conventional methods 
of radiation or chemotherapy to control the growth of residual tumor cells (90).  
Immunotherapies may require a complex approach of promoting effector immune responses 
while diminishing suppressive immune responses (1-4, 30, 90, 91).  Dendritic cell vaccines, 
ACT therapies, and even doses of antibodies may need to be coupled with lymphodepletion 
or cytokine therapy to inhibit suppressors of the response, such as Tregs (1-4, 30, 90-92).  
Additionally, patients may be genetically prone to suppressive immune responses (for 
example IL-10 production), which may require more aggressive approaches to inhibiting 




 Tc1 cells had previously been shown to deliver more effective tumor therapy 
compared to Tc2 cells (5-11).  Data suggested that Tc1 cells may migrate more efficiently 
than Tc2 cells after transfer into tumor-bearing mice (6, 7,10).  We developed a model to 
examine the migration and tumor infiltration of these donor cells in vivo, as well as examine 
whether antigen expression increased tumor infiltration (See Chapters 2 and 3) (12).  We 
found that Tc1 cells were more abundant in TDLNs and tumors than Tc2 cells, even in sites 
of antigen-negative tumors (Figures 3.1 and 3.5) (12).  We phenotyped the adhesion 
molecule expression of the donor cells before and after transfer (Figures 3.2-3.4) (12).  Tc1 
cells expressed higher levels of CD62L, CD44, LFA-1, and PSGL-1 in vitro compared to 
Tc2 cells (Figure 3.2) (12).  After three days in vivo, the Tc1 cells still expressed higher 
levels of these molecules compared to Tc2 cells (Figures 3.3 and 3.4) (12).  On day 7 after 
transfer, only CD62L expression was higher on Tc1 cells than Tc2 cells (Figures 3.3 and 3.4) 
(12).  All of the CD8+ T cells in the tumors expressed high levels of CD44, LFA-1, and 
PSGL-1 (Figures 3.4 and 3.7) (12).  We define this adhesion molecule expression as a tumor 
infiltrating phenotype, because this phenotype was expressed by both donor and host CD8+ T 
cells in the antigen-positive and antigen-negative tumors of Tc1 and Tc2 treated animals 
(Figures 3.4 and 3.7) (12).  The expression of cognate antigen by the tumors did not appear to 
affect the expression of this tumor infiltrating phenotype but did affect the number of 
infiltrating Tc1 and Tc2 cells (Figures 3.5 and 3.6) (12).  These findings are important for 
advancing our understanding of adoptive cell therapies in the treatment of tumors, 
particularly the importance of generating donor cells with the appropriate phenotype to 
facilitate the necessary migration and tumor infiltration after transfer. 
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 We believe that Tc1 cells migrate and infiltrate tumors more efficiently than Tc2 cells 
and that the differences in the expression of a tumor infiltrating phenotype before transfer 
contributes to the observed differences in Tc1 vs. Tc2 cell trafficking.  However, our work 
suggests many future studies:  1) We still need to demonstrate the requirement for the tumor 
infiltration phenotype by donor cells, perhaps by sorting for Tc1 and Tc2 cells that express 
this phenotype in vitro before transfer and comparing Tc1 vs. Tc2 cell trafficking.  2) How 
Tc1 cells regulate higher expression of these adhesion molecules or whether the efficiency of 
adhesion molecule function is different for Tc1 and Tc2 cells is unknown.  Regulation of 
gene expression by T-bet, resulting in expression of different isoforms and modifications of 
the adhesion molecules, is a strong candidate for transcriptional differences between Tc1 and 
Tc2 cells.  This is supported by the increased expression of T-bet we observed in Tc1 cells 
compared to Tc2 cells, but T-bet activity still needs to be confirmed.  3) Differences in 
mobility of adhesion molecules in lipid rafts and in SMAC formation is also another possible 
explanation for differences in Tc1 and Tc2 cell trafficking.  4) Furthermore, antigen 
expression and chemokine expression, particularly CXCR3 ligand IP-10, by tumors may 
affect Tc1 and Tc2 cell trafficking differently.  In general, it is still unclear how antigen 
promotes tumor infiltration by CD8+ T cells or which chemokines are responsible for tumor 
infiltration by CD8+ T cells, especially donor cells.   
Although we have contributed significantly to our knowledge of Tc1 vs. Tc2 biology 
and the use of polarized cells for ACT therapy, many questions remain.  Future studies 
addressing these questions will begin to provide invaluable information for improving ACT 
therapies for use in clinical trials as well as the contrasting role of Tc1 vs. Tc2 cells.  Perhaps 
Tc1 and Tc2 cells may be appropriate for different therapies, migrating preferentially to 
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different tissues or responding more effectively against different diseases.  Undoubtedly, this 
is a solid beginning to broad future for investigating Tc1 vs. Tc2 trafficking and the use of 
Tc1 and Tc2 cells for therapies. 
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CD43 Expression on Tc1 and Tc2 cells in TDLNs and tumors  
of Tc1 and Tc2 treated animals 
 Earlier we demonstrated that Tc1 and Tc2 cells express different levels of adhesion 
molecules in vitro, including PSGL-1, particularly after restimulation.  After transfer into 
tumor bearing animals, Tc1 cells expressed higher levels of PSGL-1 on day 3 in TDLNs 
compared to Tc2 cells, but on day 7, both Tc1 and Tc2 cells expressed high levels of PSGL-
1.  In both antigen-positive and antigen-negative tumors, all donor and host CD8+ cells 
expressed high levels of PSGL-1.  Therefore, we concluded that high PSGL-1 expression is a 
phenotype of tumor infiltrating CD8+ cells, one characteristic of a “tumor infiltrating 
phenotype” (Chapter 3).  In order to evaluate why Tc1 cells have higher cell surface levels of 
PSGL-1, we examined the gene expression of PSGL-1 as well as the gene expression of 
molecules known to regulate PSGL-1 in CD4 T cells, using real time RT-PCR (1-4).  We 
also examined the gene expression of another selectin ligand, CD43 (1).  While we did not 
find a difference between the gene expression of PSGL-1 by Tc1 and Tc2 cells, we did find a 
significant difference between the gene expression of CD43 in Tc1 vs. Tc2 cells.   
 CD43 is one of the ligands for P-selectin (1).  Due to the increased gene expression of 
CD43 in Tc1 vs. Tc2 cells in vitro, we examined the cell surface levels of CD43 on Tc1 and 
Tc2 cells in vivo after transfer.  According to the methods described in Chapter 3, we 
transferred GFPxP14 Tc1 or Tc2 cells into tumor bearing animals and subsequently 
evaluated CD43 expression by flow cytometry.  We found that on day 3 after donor cell 
transfer, Tc1 cells expressed significantly more CD43 in TDLNs of antigen-negative and 
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antigen-positive tumors (Figure A1).  In tumors on day 7, Tc1 cells expressed higher levels 
of CD43 only in antigen-postive tumors (Figure A1).  Although the majority of donor cells in 
the tumors are positive for CD43 expression on day 3 and day 7, there are donor cells that are 
negative for CD43 expression.  Therefore, it does not appear that CD43 expression is a 
component of the “tumor infiltrating phenotype” described earlier (Chapter 3).  Interestingly, 
the expression of CD43 in Tc1 vs. Tc2 cells in TDLNs is different on day 7 (but not day 3) 
for TDLNs of antigen-negative vs. antigen-positive tumors.   In TDLNs of antigen-negative 
tumors, Tc1 and Tc2 cell staining profiles are broad, with Tc1 cells having a population peak 
at high CD43 expression and Tc2 cells having a population peak at minimal CD43 
expression.  As stated above, this CD43 expression is significantly different for Tc1 and Tc2 
cells.  However, in the TDLNs of antigen-positive tumors, both Tc1 and Tc2 cells have 
narrow expression profile, with a population peak at a high level of expression.  These data 
suggest that antigen may promote up-regulation of CD43 expression by antigen-specific T 
cells.  How this may occur is unclear.  To our knowledge, there are no reports on CD43 






























































































Figure A1:  CD43 expression by Tc1 and Tc2 cells in TDLNs and tumor sites of 
antigen-negative and antigen-positive tumors.  Following the methods in Chapter 3, we 
stained cells in TDLNs and tumors for CD43.  Gated GFP+CD8+ cells were examined, and 
the MFI of CD43 expression on Tc1 (top #) and Tc2 (bottom #) cells was determined.  
Histograms show the profile for Tc1 (gray line) and Tc2 (black line) cells.  





A Brief Study on Acute Ultraviolet Light Exposure in Aged Animals 
In addition to investigating Tc1 and Tc2 cell migration and tumor infiltration in vivo, 
we briefly examined how acute exposure to ultraviolet light (UV) affects T cell responses in 
aged animals.  Aging and UV exposure alter T cell responses (5-8).  Knowledge of how 
either aging or UV exposure promotes immunosuppression is not clear.  However, we do 
know that both aging and UV exposure affect CD4+ T cells (5-8).  Therefore, we chose to 
evaluate CD4+ T cells in aged animals either untreated or exposed to UV compared to 
untreated or UV exposed young animals.   
The CD4+ T cell population includes Treg cells known for their suppressive activity 
of both effector CD4+ and CD8+ T cells (9).  Because both UV exposure and aging alter T 
cell responses, we wanted to examine whether Treg cells are more abundant in aged or UV 
exposed animals.  Treg cells are identified as CD4+CD25+ and also have been reported to 
express intermediate levels of CD45RB (9).  Therefore, we chose to evaluate the percentage 
of cells expressing this phenotype in the spleens of young vs. aged animals that were 
untreated or exposed to UV.  Splenocytes were stained with fluorochrome-conjugated 
monoclonal antibodies specific for CD4, CD25, and CD45RB and the numbers of 
CD4+CD25+CD45RBint determined by flow cytometry.   
 When we compared splenocytes from control vs. UV exposed young animals, we 
found that UV exposed young animals had a significantly higher percentage of cells with the 
Treg phenotype (Figure A2.1).  We also found this to be the case for control vs. UV exposed 
old animals (Figure A2.1).  In addition, when we compared the percentage of cells with the 
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Treg phenotype in control young vs. old animals, we found that old animals had a 
significantly higher percentage of Treg cells (Figure A2.1).  Therefore, it appears that both 
age and UV exposure increase the numbers of Treg cells.  It is important to note that 
identification of Treg cells based on the cell surface phenotype is not the most accurate 
method of identifying Treg cells.  The most definitive marker for Treg cells is expression of 
the forkhead-winged-helix transcription factor Foxp3 (9).  Therefore, we cannot definitively 
say that Treg cells are higher in UV treated vs. control and old vs. young animals.  We can 
only conclude that cells with the Treg phenotype of CD4+CD25+CD45RBint are increased. 
 Because we observed a higher percentage of cells with the Treg phenotype in aged 
animals or animals exposed to UV and Treg cells suppress proliferation responses of effector 
T cells, we then evaluated T cell proliferation in UV exposed aged animals vs. untreated aged 
animals.  We stimulated splenocytes from these animals with either polyclonal stimulator 
concanavalin A or the LCMV p33 peptide that stimulates CD8+ T cells.  After 48 hours of 
culture, we assessed cell proliferation using alamar blue.  Basal level of proliferation was 
determined from unstimulated cultures.   We found that splenocytes from the old animals 
proliferated in response to both peptide and concanavalin A (Figure A2.2).  Importantly, 
proliferation of the splenocytes from the UV exposed old animals was significantly lower 
than controls (Figure A2.2).  This suggests that UV exposure does impair proliferative 
responses in old animals.  Whether this impaired proliferation is due to Treg cells is not clear.  
Future studies will need to confirm the presence of Treg cells by Foxp3 staining and confirm 




















































Figure A2.1: CD4+CD25+CD45RBint cells in young and old animals following acute 
exposure to UV.  Young (8-12 weeks old) or old (12 months old) P14 transgenic mice 
specific for the p33 peptide were shaved on their dorsal side and either not exposed (control) 
or exposed to UV.  Four animals were used per group. Animals were exposed to UV for 30 
minutes per treatment.  A total of 6 treatments were given over a 2 week period, with only 3 
treatements per week.  Each athree times a week for 2 weeks for a total of 6 doses.  The total 
acute UV dose was 3 hours, or approximately 4.1J/m2.  2 days following the last exposure to 
UV, splenocytes of the treated mice and control mice were harvested.  Single cell 
suspensions were stained for CD4, CD25, and CD45RB.  Cells samples were run on a 
FACSCalibur (BD Bioscience).  Data for gated lymphocytes were analyzed using Summit 











































Figure A2.2: Proliferation of T cells in control vs. UV exposed old animals.  Old P14 
mice  (12 months old) mice were shaved on their dorsal side and either not exposed (control) 
or exposed to UV.  Four animals were used per group. Animals were exposed to UV 
according to methods in Figure A2.1.  2 days following the last exposure to UV, splenocytes 
of the treated mice and control mice were harvested and stimulated in vitro using LCMV p33 
peptide or concanavalinA.  Unstimulated cells were cultured as a control for basal 
proliferation.  After 48 hours, alamar blue was added to the culture and after 4 additional 
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